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11 Introduction
1 Introduction
1.1 Importance and principal structure of the lung 
The function of the mammalian lung is the exchange of gases (oxygenócarbon dioxide) with the 
environment. Air enters the body via the upper respiratory tract (nose, mouth and throat) and 
gets into the lung - the lower respiratory tract. Beginning with the trachea, the lower respiratory 
tract branches at the main bronchus into the left and right lung harboring two and three lobes, 
respectively. From the hilus, the lobar intrapulmonary bronchi then branch further into terminal 
bronchioli, respiratory bronchioli, alveolar ducts and end in the alveolar sacs (figure 1). The 
tracheobronchial tree including the terminal bronchiole is considered as the air conducting part, 
whereas the part distal is considered as the respiratory part, which represents a gas exchange area 
of 50-100 m2 in humans (84).
Mammalian tracheobronchial branching architectures are complicated and cannot be idealized to 
one branching system. Branching of conducting airways in humans is considerably asymmetrical 
and asymmetry may have an important effect on airflow. Three idealized branching patterns are 
commonly recognized for different species: (i) monopodial (at the branching point a small segment 
may branch from the main, or parent stem), (ii) dichotomous (the parent segment may divide into 
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Figure 1: The tracheobronchial tree of the human lung. Air rich in oxygen (O
2
) enters the lung via the 
trachea and is conducted by the airways down to the alveoli, where the gas exchange against carbon dioxide 
(CO
2
) from blood takes place. On the left, the airway generation (AG) refering to its according anatomical 
structure is depicted.. The figure was modified according to Klinke and colleagues (84)..
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two equal daughter segments) and (iii) polychotomous (the parent segment may divide into many 
daughter segments) (83).
A cross-section of a conducting airway reveals a concentric anatomic structure (figure 2). The 
airway lumen is faced by a single cell layer, the epithelium, lying on the basal membrane. The 
airway smooth muscle (ASM) cells form a thin bundle around the airway. The purpose of ASM in 
the airways remains contentious, but certainly contraction of ASM is responsible for the excessive 
airway narrowing observed in asthma (77). In humans, ASM are found down to the respiratory 
bronchioles, whereas cartilage is only interspersed in the conducting airways.
Removal of particles or microorganisms from the lung is achieved by mucociliary clearance, i.e. the 
mucus – produced by goblet cells or submucosal glands – forms a continuous layer, to which the 
foreign bodies stick, that is transported by the beating cilia towards the upper respiratory tract 
(84). Cilia and mucus are not found in the alveoli as they would impair the gas exchange. At this 
site, protection against foreign particles is achieved by alveolar macrophages. They phagocytize 
the foreign particles and enzymatically degrade them or, if this is not possible, the macrophages 
migrate ameboidly towards the conducting airways and are then removed by mucociliary clearance 
(84).
Airway lumen
Mucus
Submucosal gland
Vasa privata
Goblet cellCapillary plexuses
Alveolar septae
Airway smooth muscle
Cilia
EpitheliumBasal membrane
Submucosa
Mucosa
Cartilage
Figure 2: Cross-section of an airway. The concentric structure possesses a single cell layer – the epithelium 
which is ciliated - facing the airway lumen and lying on the basal membrane. A thin bundle of airway smooth 
muscle cells follows. The vasa privata provide the lung with blood, whereas the gas exchange of oxygen and 
carbon dioxide takes place at capillary plexuses. Tethering forces are conducted by the alveolar septae. For 
more details please see the text.
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The vasa privata originate from the systemic circulation and provide the lung with blood. In 
contrast in the pulmonary circulation, the pulmonary artery and vein branch out and form 
capillary plexuses at alveolar sites where gas exchange takes place between air and blood (129). 
Tethering forces of the parenchyma, pulmonary pressure and partially also cartilage keep the 
airways in an open uncollapsed state. The parenchyma consists of alveolar ducts, alveolar sacs, 
alveoli and the airspaces contained within these structures. In the inflated lung the parenchyma 
constitutes approximately 80-90% of the lung volume and consists of around 70% airspace and 
30% gas exchange tissue which surrounds the airspace (106).
1.2 Autonomic innervation of the lung
The mammalian nervous system is divided into the central- and peripheral nervous system. The 
central nervous system is comprised of the brain and the spinal cord, whereas the peripheral 
nervous system consists of all somatic and autonomous nerves including ganglions. The somatic 
nervous system mediates between the organism and its environment. It is associated with 
conscious perception, voluntary body movements via skeletal muscles and rapid signalling. In 
contrast, the autonomous nervous system mediates between the organism and its organs. It 
is responsible for body homeostasis and the regulation of organ functions depending on the 
environmental conditions. It functions unconsciously and involuntarily. Both, the somatic and 
the autonomic nervous system, contain afferences and efferences (figure 3). Afferences are all 
neural pathways originating in the periphery (e.g. skin, organs) and running to the central nervous 
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Figure 3: Interconnections between the peripheral and central nervous system. The peripheral nervous 
system (light grey) contains both afferences and efferences. Signals originating in the periphery are conducted 
via the afferences to the central nervous system (brain + spinal cord; dark grey), become integrated and are 
then fed back to the periphery via efferent nerves resulting in an adaptation of the organism to the stimulus. 
The upper panels reflect the somatic nervous system and the lower panels the autonomous nervous system.
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system. By contrast, efferences are all neural pathways running from the central nervous system to 
the periphery (e.g. voluntary muscles, smooth muscles, vessels or glands) (51).
The autonomous nervous system is further subdivided into the sympathetic and parasympathetic 
nervous system as well as the enteric nervous system innervating the intestinal wall. Usually, an 
organ is innervated by both sympathetic and parasympathetic nerves antagonizing each other. 
Sympathetic nerve fibers are associated with the spinal cord (thoracic vertebrae 1-12 and lumbar 
vertebrae 1-4), whereas parasympathetic nerve fibers originate from the brain stem and the sacral 
vertebrae 2-4 (51). In the lung, sympathetic fibers are associated with the thoracic vertebrae 1-5 
and parasympathetic fibers with the 10th cranial nerve (Nervus vagus) (129). With respect to 
the neurotransmitter involved at the neuromuscular synapse there exist three types of nerves: 
sympathetic noradrenergic nerves, parasympathetic cholinergic nerves and nonadrenergic 
noncholinergic (NANC) nerves (9; 32; 49). Moreover, nerve fibers are distinguished by their 
conduction velocities into C- (0.3-2 m/s), Aδ- (3-8 m/s) and Aδ/γ-fibers (10-50 m/s) (97; 174).
Nervus vagus
Sympathetic
postganglionic NANC efference
Cholinergic efference
Afferent
fiber
Airway lumen
Epithelium
ASMCatecholamines
from circulation
NE
NO,VIP
M
ACh
SP,NKA,NKB
β
NKR
VR
Figure 4:  Innervation  of  the  airway  smooth  muscle  (ASM). The ASM is innervated by cholinergic, 
adrenergic and nonadrenergic noncholinergic nerves (NANC) (9; 142). Excitatory and inhibitory components 
run side by side, in which excitatory mechanisms lead to ASM contraction and inhibitory mechanisms to 
ASM relaxation. The excitatory cholinergic innervation is present in the airways from the trachea down to 
the peripheral bronchi. Bronchoconstriction via excitatory NANC is mediated via subepithelial C-fiber sensory 
afferents that release tachykinins (neurokinin (NK) A and B, and substance P (SP)). Next to the noradrenergic 
inhibitory system originating from the adrenal medulla or sympathetic ganglia, inhibitory NANC innervation 
has been confirmed, in which vasoactive intestinal polypeptide (VIP) and nitric oxide (NO; diffusing through 
ASM membrane and activating intracellular soluble guanylyl cyclase) are involved as neurotransmitters. Except 
for the cholinergic nerve component which seems to be present in all mammals, the innervations of the ASM 
show a considerable variability among different species. ACh, acetylcholine; β, β-adrenoceptor; M, muscarinic 
acetylcholine receptor; NE, norepinephrine; NKR, NK receptor; VR, VIP receptor. The figure was modified 
according to Andersson and Grundström (9).
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The autonomic nerves regulate many aspects of airway function, e.g. ASM tone, mucus 
secretion and bronchial microcirculation (143). Upon activation, the nerves release their inherent 
neurotransmitters, which then have a post-junctional effect on their end organ. With respect to the 
ASM, neurotransmitters initiate bronchoconstriction or relaxation (figure 4). Bronchoconstrictive 
neurotransmitters are for instance acetylcholine, which is released by parasympathetic cholinergic 
nerves, and the tachykinins substance P (SP), neuropeptide K, neurokinin (NK) A or B, which are 
released from excitatory NANC (eNANC). ASM relaxation is caused by β2-receptor stimulation 
after activation of sympathetic adrenergic nerves or by the release of vasoactive intestinal 
polypeptide (VIP) or nitric oxide (NO) from inhibitory NANC (iNANC) (9; 59).
Innervation of the ASM differs between species as well as within species along the tracheobronchial 
tree. Spina and colleagues (158) studied the sensory nerve functions of different species and found 
that the relative tissue content of the neuropeptides calcitonin gene related peptide (CGRP) and 
SP was much higher for guinea pigs than for rabbits and marmosets, which had equal levels. In 
some cases the same neuropeptides can even have opposing effects: Whereas SP or NK A cause 
relaxation of tracheal preparations from Sprague-Dawley and Wistar rats, they lead to contraction 
of tracheal preparations from Fischer 344 rats (42; 56; 81; 165). Within guinea pigs, cholinergic 
nerves dominate over tachykinergic at the trachea, whereas tachykinergic nerves dominate at the 
bronchus (8). The human lung contains ASM constrictive cholinergic and eNANC nerves, and 
ASM relaxation is mainly due to iNANC nerves whereas sympathetic adrenergic nerves may play 
only a minor role (32).
1.3 Mechanisms of neurally induced ASM contraction
The parasympathetic nervous system is the dominant bronchoconstrictor mechanism in all 
mammals (14). Acetylcholine is released from nerve terminals and binds to muscarinic (M) receptors 
at different sites throughout the lungs. The M1 receptor is localized on parasympathetic ganglia 
and is thought to primarily facilitate cholinergic neurotransmission by nicotinic acetylcholine 
receptors. M2 receptors on the pre-synaptic nerve terminals control acetylcholine release in a 
feedback manner, limiting excessive acetylcholine liberation. Moreover, M2 and M3 receptors are 
found on the ASM cells. M3 receptor activation leads to ASM contraction, a process facilitated 
by M2 receptors by counteracting cAMP-mediated relaxant pathways (21). Regarding eNANC 
innervation released tachykinins bind to NK receptors located on the ASM. SP binds principally to 
the NK1 receptor, whereas NK A and NK B bind to NK2 and NK3 receptors, respectively (6). Both, 
M and NK receptors belong to the family of heterotrimeric guanine nucleotide-binding protein 
(G protein) coupled receptors (GPCR). M3 and NK1-3 preferentially couple to the Gq/11 protein
(6; 21). Receptor stimulation results in dissociation of the G protein and subsequent activation of 
the phospholipase C by G
βγ
. Phospholipase C hydrolyzes phosphatidylinositol-4,5-bisphosphate to 
diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate (IP3) (5). Then IP3 binds to the IP3 receptor at 
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the sarcoplasmic reticulum (SR) causing the release of calcium from intracellular stores (115) and 
resulting in a 10000-fold increase in intracellular calcium concentration (72). In a resting (relaxed) 
ASM cell the intracellular free calcium ion concentration is approximately 100-200 nM (147). The 
elevated intracellular calcium concentration causes the formation of the calcium/calmodulin 
complex, which activates the myosin light chain kinase (MLCK). The contractile apparatus of the 
ASM consists of actin and myosin filaments and accessory and regulatory proteins. Phosphorylation 
of the myosin light chain by MLCK enhances its intrinsic adenosine triphosphatase activity and 
subsequent mechanical interactions with actin. Finally, this results in the sliding of the myosin 
molecule along the actin filament (72).
ASM contraction can also occur after increases of cytosolic calcium concentration due to 
calcium entry from extracellular sites via voltage gated calcium channels, the reverse mode of 
the sodium calcium exchanger (NCX), voltage independent influx via transient receptor potential 
(TRP) channels or activation of the ryanodine receptor at the SR (72; 115; 147). However, these 
mechanisms are beyond the scope of neurally induced ASM contraction and are therefore not 
explained in detail here.
Another mechanism leading to ASM contraction operates by the inhibition of the myosin light 
chain phophatase (MLCP). Thereby, the dephoshorylation of the myosin light chain is prevented 
and ASM contraction is promoted. Inhibition of MLCP is due to activation of the Rho-kinase 
pathway in response to G12/13 stimulation (62; 186) or due to DAG formation after Gq/11 stimulation. 
DAG activates the protein kinase C (PKC) (5). PKC in turn phosphorylates the following protein 
PKC activated phosphatase inhibitor (CPI)-17, which functions as inhibitor of the catalytic subunit 
of MLCP (62; 186).
Phamacologically, ASM contraction can be inhibited by receptor antagonists which is also of 
clinical relevance, e.g. tiotropium in chronic obstructive pulmonary disease (COPD) (134). A variety 
of anticholinergics, such as atropine, 4-DAMP, AQ-RA, gallamine, DAU 5884, methoctramine, 
pirenzepine, AF-DX 116, ipratropium or tiotropium have been developed and show different 
specificity concerning the M receptor subtypes (62). Selective antagonists of the NK receptors are 
for instance aprepitant, SR140333, LY303870, CP99994, and RP67580 for NK1, GR94800, GR159897, 
MEN10627, SR48968 and MEN11420 for NK2 or SR142802, SB223412 and PD157672 for NK3 (6).
1.4 Mechanisms of neurally induced ASM relaxation
ASM relaxation is caused either by sympathetic or iNANC signalling. In sympathetic signalling, 
norepinephrine functions as neurotransmitter binding to β-receptors on the ASM (19). In iNANC 
signalling, VIP or NO are involved as neurotransmitters binding to the VIP receptor on ASM or 
interfering with the cyclic guanosine monophosphate (cGMP) pathway in ASM, respectively 
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(22; 101; 116; 178). Both, the β-receptor and the VIP-receptor belong to the family of GPCRs 
coupling to the Gs protein (6). Upon dissociation of Gs, in response to receptor stimulation, the 
membrane bound adenylyl cyclase becomes activated catalyzing the formation of cyclic adenosine 
monophosphate (cAMP) from adenosine triphosphate (ATP) (5; 20; 98). Increased cAMP levels are 
responsible for ASM relaxation due to several mechanisms: On the one hand, cAMP may promote 
the efflux of calcium to the extracellular space via NCX or via calcium-ATPases into the SR. On the 
other hand cAMP may activate the protein kinase A (PKA) (85). The PKA leads to phosphorylation 
of the MLCK preventing MLC phosphorylation (58) or PKA attenuates RhoA phosphorylation (92), 
which decreases Rho association with its downstream target Rho kinase (44).
NO activates the soluble guanylyl cyclase forming cGMP, which activates the protein kinase G 
(PKG). PKG causes smooth-muscle relaxation by mechanisms that are still being defined and that 
include reduction in cytosolic calcium (by enhanced calcium export and/or by reduction in IP3 
receptor-mediated calcium-mobilization) and dephosphorylation of MLC (by activation of MLCP 
and/or by sequestration of MLCK in a phosphorylated form, which is inaccessible for calcium/
calmodulin complexes) (20).
ASM relaxation can be influenced pharmacologically. With respect to β-receptors, a variety 
of antagonists and agonists are established. Antagonists are for instance the β-blockers, 
propranolol and arterenol. Agonists have clinical relevance in the treatment of asthma and are 
for instance salbutamol, isoproterenol, indacaterol, salmeterol or formoterol, which are classified 
as short or long acting β-agonists (SABA/LABA) depending on their duration of action (125). 
Moreover, direct blocking of catecholamine release from adrenergic nerves can be achieved 
by the application of guanethidine (52). Small peptides resembling the growth hormone 
releasing factor are considered as antagonists at the VIP-receptor (6; 63; 182). NO-signalling is 
antagonized by NO synthase inhibitors such as N
ω
-nitro-L-arginine methyl ester (L-NAME) (139) or 
N
ω
-nitro-L-arginine (L-NNA) (102; 103).
1.5 Electric field stimulation (EFS) of lung tissue preparations in organ baths
Application of an electric field across isolated airway preparations results in activation of intrinsic 
nerves, the release of neurotransmitters, and response of the ASM to these neurotransmitters (52). 
Previously, EFS has been studied in three types of airway preparations, i.e. tracheal strips, bronchial 
strips and parenchymal strips (52), which were mounted in organ baths and faced by parallel 
platinum electrodes. The electrodes can be wire or flat stock placed parallel to the preparation 
or ring electrodes placed at each end of the tissue (52). These models have been extremely useful 
for understanding the neural control of airway tone in different species e.g. mouse, rat, guinea pig, 
ferret, cat, dog, horse or human (8; 11; 49; 57; 61; 71; 80; 93; 104; 125; 183; 184; 190), and continues to 
do so (25; 125). However, the organ bath method has some disadvantages: First, it can be applied 
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only to relatively large airways and preparations from the lower airways of smaller mammals are 
difficult to obtain. For example in rats, studies of the innervation are characterized only down to the 
eighth generation (52). However, innervation is unevenly distributed along the tracheobronchial 
tree. For instance, in guinea pig trachea cholinergic nerves predominate over tachykinergic nerves, 
whereas the latter predominate in the bronchus (8). In vivo parasympathetic vagal stimulation 
and tantalum roentgenography showed a higher bronchospasm in intermediately sized airways 
compared to larger airways in dogs or cats. Therefore, methods to examine smaller sized airways 
in different species are needed (124). Second, organ bath methods are often performed under 
either isometric or isotonic conditions and require a muscle preload. This creates potential 
problems: the preload is artificial and may influence the result or even damage the smooth 
muscle (52). Furthermore, contractions are not auxotonic as in vivo, where the ASM shortens 
against an increasing load imposed by the attachments of the surrounding lung parenchyma, 
parallel elastic elements (i.e. extracellular matrix) and mucosal folding (34; 52; 96). More recently, 
some of these problems have been solved by the development of servo-controlled force-length 
transducers that adjust airway preparations to match a muscle length that was determined before 
the specimen was prepared (25; 26). Third, the smaller the airways are the smaller is the amount 
of smooth muscle and quantification of weak contractions requires very sensitive equipment. 
Spiral tissue preparations, used to increase contractions, are hampered by misalignment of the 
smooth muscle from the longitudinal axis and force generation is lost to the coil (52). Fourth, 
organ bath experiments require a relatively large buffer volume, generally more than 5 mL. 
This is disadvantageous, if expensive substances have to be tested and/or a high throughput of 
experiments is intended. Fifth, in whole tissue preparations (i.e. parenchymal strips) contractions 
from airways or vessels cannot be distinguished (52).
1.6 Precision-cut lung slices (PCLS)
PCLS are a relatively new in vitro method in pulmonary research. PCLS are lung tissue slices of 
uniform thickness of 200 - 300 µm, which are prepared from agarose instilled lungs by means of a 
Krumdick tissue slicer and which are viable for at least 72 h under cell culture conditions (111; 159). 
In 1996, Martin and colleagues (111) described the preparation and study of airway responses in 
PCLS for the first time. Originally developed for rats, the PCLS method has been adopted to other 
species such as mice (34; 68), guinea pigs (145), horses (181), sheep (151), non-human primates 
(155) and humans (145; 163; 188). Depending on the species 10 to more than 50 slices can be 
obtained from one animal. Therefore, this method is very economical in terms of experimental 
costs and animal use, thus contributing to Russell’s and Burch’s (149) 3Rs (refinement, reduction, 
replacement) of animal protection: The PCLS Method has the potential to (i) refine the multiple 
physiological measurements, (ii) reduce the number of animals by a factor of 10 to 50 and (iii) 
replace animals when human lung tissue is used (110).
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PCLS have been extremely useful in pharmacological (69; 107; 145; 152; 188; 189) and toxicological 
studies (68; 127; 128) because they resemble the intact respiratory tract of the in vivo situation in 
morphology and functionality. Some advantages of the PCLS method are that airway contractions 
are somehow auxotonic as the airways are embedded in the surrounding tissue (34), that 
contractions of vessels and airways can be distinguished (108), that only small buffer volumes are 
needed, that many slices can be obtained from an individual so that different conditions can be 
tested at the same subject and that small airways are accessible allowing to study the complete 
tracheobronchial tree down to the peripheral lung (111; 152; 189). Even biochemical analysis can 
be performed on PCLS, i.e. gene expression profiles can be analysed after reverse transcription 
polymerase chain reaction (38) or intracellular calcium fluxes can be measured in multiphoton 
microscopy (39; 145).
Small airways are defined by their inner diameter being less than 2 mm in human and less than 
780 µm in rat airways (189; 191). As a result of their relative inaccessibility, the role of small airways 
is difficult to assess and maybe because of these problems small airways have been considered as 
a silent zone in the past. Since in PCLS the airway diameter is easily accessible, this method offers a 
novel way to study airway responses in peripheral airways (110). The smallest airways being analyzed 
by Wohlsen and colleagues (189) in PCLS from rat were of 50 µm in diameter, corresponding 
roughly to the terminal bronchioles. Bronchoconstriction in PCLS has been studied in response to 
exogenously administered mediators of the early allergic response (e.g., methacholine, histamine, 
serotonin, thromboxane (TXA), leukotriene (LT), endothelin) and in response to allergens after 
passive or active sensitization (34; 189). Smaller airways in PCLS are more reactive to methacholine, 
serotonin, the thromboxane prostanoid (TP) receptor agonist U46619 and allergens in lungs 
of different species (112; 188; 189). Different explanations for these longitudinal differences in 
airway responsiveness are possible: for instance, heterogeneous receptor distribution along the 
airways, as shown for VIP (33; 137), tachykinin (55), SP (132), and histamine (28) or varying ASM 
thickness (thickness is more pronounced in small than in large airways) (48), which might result 
in differences in airway reactivity (120; 162). This last argument is contradicted by findings that 
endothelin contracted airways independent of their size (112), while small airways react stronger 
to methacholine and TXA (111; 112). Given the importance of small airways for asthma and COPD 
(160; 188; 189), the possibility to study different airway generations in PCLS is of clinical relevance.
Mucociliary clearance is an important defense mechanism that clears foreign particles and 
chemicals from the airways to maintain healthy lungs. A key parameter determining the rate of 
mucus clearance is the ciliary beat frequency (CBF). The density (cilia per cell and number of 
ciliated cells) and length of cilia are greater in the trachea than in small airways and this correlates 
with an increase in mucus transport and CBF toward the oropharynx (41). Hence, beside broncho- 
and vasoconstriction, measuring the CBF has been addressed in PCLS from mice, rats and humans 
(41; 187; 188). CBF in those species varied from 23.1 - 26.5 Hz in mice to 12.7 - 15.6 Hz in rats and 
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4.8 - 12.9 Hz in humans. Although species variation may occur, PCLS serve as a suitable model to 
examine regulation of CBF in response to physiological parameters (e.g. temperature) (41) or drug 
interference (e.g. cAMP elevating agents such as roflumilast), which have shown beneficial effects 
in COPD or asthma (187).
Overall, as results obtained from PCLS are predictable for responses of the entire intact lung (110), 
PCLS are of great use in pulmonary toxicology and pharmacology, i.e. development of drugs for 
asthma and COPD. Certainly, human PCLS provide a unique opportunity to save animals and to 
get clinically relevant data at the same time.
1.7 Asthma and COPD
Bronchial asthma and COPD have a high personal as well as societal, and economical impact 
(177). Chronic lower respiratory tract diseases are the fourth-leading cause of death and the major 
cause of sickness in the United States (123). Worldwide, they are currently the fifth-leading cause 
of death and the World Health Organization projects they will become the third-leading cause by 
2030 (154). Therefore, it is critical to understand their underlying pathogenic mechanisms in order 
to develop new treatment strategies.
Both asthma and COPD are characterized by airway obstruction, which is variable and reversible 
in asthma but is progressive and largely irreversible in COPD. In asthma, airway obstruction is 
mainly due to bronchoconstriction, edema and plasma exudation, whereas in COPD mucosal 
inflammation, fibrosis, emphysema and mucus hypersecretion are responsible for obstruction 
(19). In both diseases, the respiratory tract is chronically inflammed (table 1), which is mediated 
by increased production of multiple inflammatory proteins, including cytokines, chemokines, 
adhesion molecules, inflammatory enzymes and receptors (19). Moreover, acute episodes of 
exacerbation are observed with increasing intensity of inflammation in both diseases (19). 
Ultimately, chronic inflammation leads to airway remodelling which affects the whole respiratory 
tract from central to peripheral airways that are less than 2 mm in internal diameter in humans, 
the so called small airways (177).
Asthma is an allergic disease, in which mast cells become activated and initiate the early 
allergic response (EAR) within minutes and the late allergic response (LAR) within hours 
leading to the typical asthma symptoms: wheezing, coughing, chest tightness and shortness of 
breathing (170). In the EAR, inhaled allergens activate mast cells, by cross-linking surface bound 
immunoglobulin (Ig) E, that degranulate and sequester preformed (histamine, proteoglycans, 
serine proteases, tumor necrosis factor (TNF)) or newly synthesized mediators (prostaglandins 
(PG), cysteinyl LT, TXA, platelet activating factor, cytokines). These mediators interact and lead 
to bronchoconstriction (17; 18; 170). The LAR appears frequently 4 - 6 hours after the EAR and 
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depends on leukocyte (eosinophils, mast cells and T-lymphocytes) recruitment due to mast cell-
derived mediators such as TNF-α and different chemokines as well as the expression of adhesion 
molecules on leukocytes and vascular endothelial cells (170). Those leukocytes initiate the second 
phase of bronchoconstriction, mucus secretion and airway swelling. Moreover, they cause tissue 
destruction, launch and maintain the chronic inflammation (170). T helper lymphocytes type 2 
(TH2-lymphocytes) have a central role in regulating the inflammatory response in allergy through 
the release of interleukins (IL). IL-4 and IL-13, stimulate B-lymphocytes to produce IgE, IL-5 attracts 
eosinophils and IL-9 stimulates mast-cell proliferation (18).
In contrast to asthma, in COPD, inhaled cigarette smoke and other irritants activate epithelial 
cells and macrophages to release chemotactic factors that attract monocytes (differentiating 
into macrophages in the lung), neutrophils, T helper lymphocytes type 1 (TH1-lymphocytes) and 
type 1 cytotoxic T cells (TC1-cells) (18). These cells, together with macrophages and epithelial cells, 
release proteases, e.g. matrix metalloproteinase 9 causing elastin degradation and emphysema. 
Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages release 
transforming growth factor-β, which stimulates fibroblast proliferation, resulting in fibrosis in the 
small airways (18).
Character Asthma COPD
Airway smooth muscle Increased Minimal increase
Basement membrane Thickened No change
Fibrosis Subepithelial Peribronchiolar
Alveolar disruption No Existent
Airway vessels Increased No change
Epithelium Often shed Pseudostratified
Goblet cells Increased Increased
Mast cells Increased and activated Normal
Eosinophils Increased Normal
Neutrophils Normal (severe: increased) Increased
Dendritic cells Increased Uncertain
T lymphocytes TH2 type TH1 and TC1 type
B lymphocytes IgE producing Increased
Cytokines IL-4, IL-5, IL-13, TNF-α TNF-α
Chemokines CCL11, CXCL8 CCL2, CXCL1, CXCL8
Lipid mediators LTD4, LTB4, PGD2 LTB4
Oxidative stress Yes Yes
Steroid response Sensitive Resistant
CCL, CC-chemokine ligand; COPD, chronic obstructive pulmonary disease; CXCL, CXC-chemokine ligand; IL, 
interleukin; LTB4, leukotriene B4; LTD4, leukotriene D4; PGD2, prostaglandin D2; TC1, type 1 cytotoxic T cell; TH, 
T helper cell; TNF, tumor necrosis factor.
Table 1: Characteristics of asthma and COPD in chronic inflammation of the lower respiratory tract 
(modified from Barnes (17; 18))
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Airway hyperresponsiveness (AHR) and airway remodelling in asthma
AHR is defined as an exaggerated airway narrowing in response to many different stimuli, e.g. 
histamine, methacholine or adenosine (15; 170). In everyday life, increased bronchial responsiveness 
may occur following allergen exposure, upper respiratory tract viral infection or industrial chemical 
contact (15). Depending on the trigger, various types of asthma exist, that are for example 
extrinsic (allergic) asthma, intrinsic asthma, exercise-induced asthma, aspirin-sensitive asthma and 
occupational asthma (35; 64).
Airway remodelling is a consequence of chronic airway inflammation and refers to structural 
changes in the lung. These are thickening of the airway wall, hyperplasia of goblet cells, hypertrophy 
of submucosal glands, increased vascularity of the airway wall, ASM hypertrophy, ASM hyperplasia 
and subepithelial fibrosis (table 1) (13; 170). The airway wall thickening may explain incomplete 
reversibility of airway obstruction in asthmatics, whereas altered goblet cells and submucosal glands 
explain mucus hypersecretion and mucus plugging (170). Moreover, the increased vascularity is 
responsible for amplified plasma protein leakage into the lung (170). The neural function is also 
influenced in asthma and a separate chapter is dedicated to that topic (chapter 1.9).
1.8 Animal models of asthma
As a consequence of the continuous increase in prevalence and morbidity in asthma, there is an 
urgent need to develop new drugs for therapy. In general, animal models provide a surrogate for 
humans to test hypotheses concerning a disease. The strengths of animal models include: (i) being 
genetically homogenous and well defined study subjects; (ii) the ability to use invasive, in vivo, 
experimental methods to identify potential mechanisms; (iii) the accessibility of tissue for in vitro 
studies; (iv) the ability to control and manipulate environmental and/or genetic factors; and (v) the 
ability to develop and test pharmaceuticals for human use (1). With regard to allergic asthma, an 
ideal animal model should develop first an EAR, second a LAR, third non-specific AHR to various 
stimuli, forth eosinophilic and neutrophilic bronchial inflammation, fifth changes in mucus 
secretion and quality, sixth alterations in airway and lung histology and seventh spontaneous 
increase in resistance of airways after prolonged or repeated allergen exposure (83; 166). However, 
so far there is no animal known with a natural disease course perfectly mimicking human asthma 
and no animal model is available that completely reproduces the multiple features of human 
asthma (table 2) (83). Hence, all established models are approaches to reflect particular aspects of 
human asthma.
Animal models of asthma are distinguished into three groups: (i) animals having naturally occurring 
recurrent airway obstruction, e.g. cats (idiopathic asthma: wheezing, cough and cyanosis) (1; 83) 
and horses (heaves) (1), (ii) animals having an AHR before any provocation in the laboratory 
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occurs (73; 135) and (iii) animals developing reversible airway obstruction and/or increased airway 
responsiveness only after challenge, among which are small laboratory animals (e.g mouse, rat and 
guinea pig) (144) but also large animals (e.g. sheep). Remarkably, sheep may also develop a natural 
sensitivity, when they encounter the allergen Ascaris suum in their natural environment (2) and 
the use of an anthelminthic is therefore required during sensitization of sheep with for instance 
house dust mite (HDM) (24).
Concerning the latter of the three groups, sensitization of the animal is a prerequisite for studying 
airway responses. In general, animals are sensitized with an allergen, which is commonly ovalbumin 
(OVA) (60; 75; 91; 117; 185) or HDM (23; 24; 27; 157), by repeated allergen challenge over days 
to weeks to establish an adaptive immune response by the animal. Many sensitization protocols 
have been developed in which the allergen is applied either intraperitoneally, subcutaneously, 
intratracheally/intralobularly or by aerosolization. In some cases, an adjuvant such as aluminium 
hydroxide or heat inactivated Bordetella pertussis organisms may be required to induce 
TH2-lymphocyte driven immune responses and ultimately the production of IgE (87).
The rat exhibits many features of airway allergy and allergic asthma that are similar to those of 
humans (table 2) (87). Therefore, the ability to extrapolate to humans is one of the advantages of this 
species. Similarities between rats and humans include (i) EAR and LAR after an allergen challenge, 
(ii) responses after a nonspecific challenge with methacholine, acetylcholine, or serotonin, (iii) IgE 
production and (iv) an accumulation of inflammatory cells (87). The ability to produce EAR, LAR 
and AHR makes the rat favorable over the mouse model (87), which is advantageous when genetic 
modifications or gene knock-outs are required to study the involvement of distinct endogenous 
proteins in the pathomechanisms of asthma (94). AHR, airway inflammation and obstruction can 
be easily reproduced in rats, although this may depend on the rat strain: Wistar rats are prone to 
Symptom Mouse Rat Guinea pig Rabbit Cat Dog Pig Sheep Horse Monkey Human
Naturally 
sensitive - - - - +/- + - + + + +
EAR - + + +/- + + +/- + - +/- +
LAR + + + + - + + + - + +
AHR + +/- + + + + - + + + +
Inflammation + + + +/- + + + + + + +
Eosinophilia + + + - + - + + - + +
Neutrophilia - - - - - + + - + - +
Remodelling - + - - + + - + - - +
EAR, early allergic response; LAR, late allergic response; AHR, airway hyperresponsiveness
Table 2: Asthma symptoms in selected animal models compared to human asthma (referring to (1; 83; 
144))
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sensitization with OVA, producing similar but less pronounced effects compared to those observed 
in Brown Norway rats (87). In contrast, Sprague Dawley rats do not develop an allergic reaction or 
an increase in IgE production under the same conditions and usually serve as a control group for 
Brown Norway rats (87). Singh and colleagues (157) studied the allergic airway response in three 
rat strains in response to HDM and found that Brown Norway rats develop strong and Sprague 
Dawley rats moderate hallmarks of asthma, whereas Lewis rats were relatively unresponsive. 
Moreover, Schneider and colleagues (153) reported that there is no pulmonary inflammation and 
no rise in IgE after an allergen challenge in Fisher and Lewis rats.
1.9 Neurogenic inflammation and neuronal plasticity
Airway inflammation associated with asthma may affect neuronal activity at several points along 
the neural reflex pathway, including the function of the primary afferent nerves, integration within 
the central nervous system, synaptic transmission within autonomic ganglia and transmission at 
the level of the postganglionic neuroeffector junction (172). Functional changes within autonomic 
nerves of the lung are termed neuronal plasticity (143). As nerves regulate many pulmonary 
functions, altered neuronal regulation in and due to inflammation is crucial to understand. It 
affects the ASM tone, airway secretions (e.g. mucus hypersecretion), blood flow by vascular 
dilation, microvascular permeability and the migration and release of inflammatory cells (16). 
These effects are attributed to actions of neuropetides and tachykinins. All these insights led to the 
concept of neurogenic inflammation (143). The basis for this term is twofold: the biological effects 
produced by tachykinins in the airways in general are proinflammatory and provide a neurogenic 
contribution to the overall inflammatory process and the stimuli that elicit tachykinin release in 
the airways include mediators of inflammation (178). For instance, inflammatory mediators such as 
bradykinin, platelet-activating factor, LTD4, lipoxin A4, PG and histamine activate and/or sensitize 
capsaicin sensitive afferents (99). Hence, capsaicin desensitization reduces bronchoconstriction, 
vasodilation and AHR in experimental animal models (guinea pig, pig and sheep) after allergen 
exposure (99). In human, capsaicin led to abolished nasal irritation by lactic acid and hypertonic 
saline as well as absent skin flare response to allergen, pointing to the involvement of sensory nerves 
in allergy (99). This is supported by the finding of increased levels of neuropeptides including SP 
in the lungs of asthmatic patients and elevated levels of NK A in bronchoalveolar lavage fluids of 
asthmatic patients following airway allergen challenge (143).
The underlying mechanisms of qualitative changes in nerve functions include enhanced reflex 
activity, increased mediator release, enhanced sensitivity of the ASM to neuropeptides and 
tachykinins as well as increased receptor-density on both ASM cells and airway neurons. Moreover, 
quantitative changes in sensory and/or motor neurons are also debated in the context of asthma 
(143). LTs or TXA, for example, are inflammatory mediators enhancing acetylcholine release by 
activating afferent sensory nerve fibres and by directly facilitating ganglionic neurotransmission 
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and acetylcholine release from vagal nerve terminals (4; 7; 21; 116; 167; 176) (figure 5). Another 
mechanism leading to an increased cholinergic outflow is neuronal M2 receptor dysfunction 
as acetylcholine induced feedback inhibition of acetylcholine release is prevented. Neuronal 
M2 receptor dysfunction has been reported to contribute to AHR in human asthma patients, 
antigen challenged animals, virus infected animals, ozone exposed animals, and animals exposed 
to organophosphate pesticides (131). In antigen challenged animals, eosinophils are recruited to 
airway nerves, where they degranulate and release major basic protein (MBP), which functions 
as a natural occurring M2 receptor antagonist (76) (figure 5). There is also a possible role of the 
inflammatory cytokine TNF-α to inaugurate M2 dependent hyperreactivity, because TNF-α directly 
inhibits M2 receptor gene expression in vitro (130). Moreover, vagally induced AHR in guinea pig 
after OVA sensitization (130) or viral infection (131) is abolished by etanercept (a human dimeric 
fusion protein consisting of the p75 TNF receptor 2 dimer linked to the fragment crystallizable (Fc) 
of IgG1), and M2 receptor expression is reconstituted by etanercept in neuroblastoma cells, which 
were treated with a supernatant of virus-infected tracheal epithelial cells (131).
The functional plasticity of neurons is under close control of neurotrophins (NT) (143). Trophe 
originates from the Greek and means nourishment. Therefore, in the context of nerves, 
neurotrophism describes a nutritive, target-derived factor that promotes growth and survival 
of neurons (142). NTs are small proteins of about 13 kDa regulating neuronal structure and 
function, i.e. neurogenesis, neuronal differentiation/survival, neuronal plasticity and neuronal 
conduction (142). The NT family classically consists of four conserved members of similar structure 
and function: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT3 and 
NT4/5. Those bind to tropomyosin-related kinase (Trk) receptors with different affinities. NGF 
preferentially binds to the Trk A receptor, BDNF and NT4 to the Trk B receptor, whereas NT3 
binds with high affinity to the Trk C receptor and lesser affinity to Trk A and B. Moreover all NTs 
bind to the low-affinity p75 neurotrophin receptor (p75NTR) (142). Originally, NTs were reported 
to be involved in neurodegenerative disorders (e.g. Alzheimer’s disease), brain tumors and spinal 
cord injury repair (142). However, there are several sources of NTs in the lung and their receptors 
are present at different sites. These lung components include nerves, immune cells, epithelial 
cells, fibroblasts, ASM, vascular smooth muscle, vascular endothelial cells and distinct immune 
cells (142). Accordingly, NTs have the potential to affect pulmonary function and structure at all 
sites. The current knowledge on NTs with respect to their importance in asthma is summarized 
in table 3.
Another neurotrophic factor is the glial-derived neurotrophic factor (GDNF). Primary sensory 
nerves are modulated by GDNF and GDNF family ligands (GFLs, e.g. neurturin, artemin, and 
persephin). GDNF and GLF selectively interact with the GDNF family receptors (GFRα1-4) (97). 
Neurotrophic factor receptor expression has been largely characterized in neurons during 
development and in neonatal animals. In contrast, there is little information regarding neurotrophic 
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Figure 5:  Irritation  of  nerves  in  inflammation  and  asthma.  Chronic inflammation leads to epithelial 
shedding activating sensory nerves, which release tachykinins. Tachykinins in turn activate inflammatory 
cells or facilitate acetylcholine (ACh) release from parasympathetic nerves. Increased Ach outflow can also 
be due to muscarinic acetylcholine receptor (M
2
) dysfunction, tropomyosin related kinase receptor (Trk
R
) 
stimulation and leukotriene (LT), prostaglandin (PG) or thromboxane (TXA) stimulation of parasympathetic 
nerves. M
2
 dysfunction results from the natural antagonist major basic protein (MBP) released by eosinophils 
or from inhibited M
2
-gene expression by tumor necrosis factor (TNF). Neurotrophic factors may originate 
from different sources inducing a phenotypic switch in nerves (Neurotrophin (NT)-3 induces inhibitory 
nonadrenergic noncholinergic nerves (iNANC) to produce substance P (SP)) or activating immune cells. For 
example, nerve growth factor (NGF) activates eosinophils and type 2 helper T-lymphocytes (T
H
2-cell). T
H
2-cells 
release IL-5, that attracts eosinophils, or IL-4, that stimulates B-lymphocytes (B-cell) to produce immunoglobulin 
(Ig) E and IgG
1
. IgE binds to the surface of mast cells, which get activated and degranulate if allergen is bound 
by IgE. Increased neurotransmitter (ACh, SP, neurokinin A (NKA), calcitonin gene related peptide (CGRP)) 
release results in increased airway smooth muscle (ASM) contraction, mucus hypersecretion and increased 
vascular leakage by binding to muscarinic- (Mr) or neurokinin receptors (NKR) on ASM, goblet cells, 
submucosal glands or vessels. ↑, increased; →/+, activating, ┤, inhibiting. For more details, please see the text.
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Components NT expressed
NTR 
expressed Effects and importance
Structure:
Nerves NGF;
BDNF; 
NT3
TrkA;
TrkB;
p75NTR
↑NGF: induced TrkA, NK1 and SP expression/content;
↑Neuronal plasticity;
↑Cholinergic outflow (BDNF);
Neurally-mediated AHR (NGF, BDNF);
↑Neurotransmitter release (NT3)
ASM NGF;
BDNF;
NT3;
NT4
TrkA;
TrkB;
TrkC;
p75NTR
↑NGF, BDNF, TrkA, TrkB, p75NTR with inflammation;
Contractility (↑with NGF, BDNF, NT4; ↓with NT3);
↑AHR (NGF);
Airway remodelling;
↑Cell proliferation (NGF)
Epithelium NGF;
BDNF;
NT3;
NT4
TrkA;
TrkB;
p75NTR
↑BDNF
↑NGF with inflammation (allergic asthma);
Airway remodelling: ↑airway thickening, ↑cell survival
Immune Cells:
Monocytes/
macrophages
NGF;
BDNF;
NT3
TrkA;
TrkB
↑NGF and BDNF with allergen challenge
T-lymphocytes NGF TrkA ↑BDNF with allergen challenge;
NGF produced by CD4+ and CD8+ T-lymphocytes;
↑NGF by TH2-lymphocytes
B-lymphocytes NGF;
BDNF;
NT3
TrkA;
p75NTR
↑NGF, BDNF and NT3 with allergen challenge
Eosinophils NGF;
BDNF;
NT3;
NT4
TrkA ↑NGF with airway inflammation
Mast cells NGF;
BDNF;
NT3
TrkA;
TrkB;
p75NTR
Allergen-induced IgE-mediated NGF release
↑, increase; ↓, decrease; AHR, airway hyperresponsiveness; ASM, airway smooth muscle; BDNF, brain-derived 
neurotrophic factor; CD, clusters of differentiation; IgE, immunoglobulin E; NGF, nerve growth factor; NT, 
neurotrophin; NK, neurokinin; NTR, neurotrophin receptor; p75NTR, p75 neurotrophin receptor; SP, substance P; 
TH2, type 2 T helper lymphocyte; Trk, tropomyosin-related kinase receptor
Table 3: Neurotrophins and their potential function in asthma (modified from (142))
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factor receptor expression in adult vagal afferent neurons of differing phenotypes, especially with 
respect to airway-specific neurons (97). Recently, Lieu and colleagues (97) showed the expression of 
GFRα1-3 and their corresponding co-signalling molecule RET in jugular neurons innervating the 
lung of guinea pig, but their physiological importance remains undetermined.
The mechanisms by which neurotrophic factors alter airway function are a current focus of 
biomedical research. Undem and coworkers (173) were the first to report a phenotypic change 
in airway tachykinergic innervation associated with allergen challenge and that NGF is a potential 
mediator for this effect. NGF increases SP expression in airway neurons and changes the neuronal 
phenotype so that large, capsaicin-insensitive nodose neurons with fast-conducting Aδ fibers 
provide a component of the tachykinergic innervation (74). AHR, as shown after ozone exposure, 
may then result from enhanced release of acetylcholine from parasympathetic nerves, since 
tachykinins bind to NK receptors on these nerves, or tachykinins, i.e. SP, cause eosinophils to 
release MBP blocking the M2 receptor on cholinergic nerves (179; 180) (figure 5). Recently, Pan 
and colleagues (138) found that the iNANC phenotype changed to a cholinergic phenotype in 
guinea pigs after repeated allergen challenge and that this change was mimicked by NT3 (figure 5). 
Physiologically, this could imply an exaggerated airway contraction, because an airway relaxant 
pattern is switched to a constrictive one, but the proof for that is yet missing. Furthermore, 
evidence is given by an electrophysiological study on airway parasympathetic ganglia from 
guinea pigs that synaptic transmission is directly potentiated by NGF, i.e. by binding of NGF to 
Trk receptors on neurons (figure 5). Using single cell recording, direct application of NGF caused 
a lasting decrease in the cumulative action potential after hyperpolarization and increased the 
amplitude of excitatory postsynaptic potentials in response to nicotinic stimulation, which was 
blocked by the tyrosine kinase inhibitor, K-252a, implicating Trk receptor involvement (65). NTs 
also exhibit profound effects on immune cells residing in airways and lung tissue, which has 
been termed immunological plasticity (143). In this regard, neurotrophins act as amplifiers of 
the locally occurring immune dysbalance. For instance, when splenic mononuclear cells from 
allergen-sensitized mice were stimulated with different concentrations of OVA in vitro, there was a 
TH2-mediated immune response, characterized by elevated IL-4 and IL-5 production as well as 
increased IgE and IgG1 synthesis (30).
The modulatory effect of nerves on inflammation or rather immune cells has been termed the 
inflammatory reflex (169). The modulatory effect can be either anti- or pro-inflammatory, and the 
role of tissue macrophages may be central to this issue. Neural anti-inflammatory regulation of 
tissue macrophages is local, fast and integrated through the central nervous system. Acetylcholine, 
originating from parasympathetic nerves, inhibits the release of cytokines from macrophages via 
activation of the α7-nicotinic acetylcholine receptor present on their surface and subsequent 
inhibition of gene transcription (169; 171). This action is anti-inflammatory, because macrophages 
typically secrete pro-inflammatory cytokines such as TNF, IL-1, IL-6 or high-mobility group box 1 
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(HMGB1) during inflammation (171). Epinephrine and norepinephrine from sympathetic nerves 
predominately inhibit TNF release but can, under certain circumstances, stimulate TNF release, 
while SP stimulates cytokine synthesis amplifying the local inflammatory response and mediating 
pain (169).
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Irritation of nerves plays an important role in chronic inflammatory lung diseases such as asthma 
and COPD. Up to date, peripheral airway innervation is poorly characterized in the mammalian 
lung. The PCLS method is a relatively new method in pulmonary research and has been established 
for different species. It allows the study of large to small airways along the tracheobronchial tree 
and has been useful to characterize airway responses to exogenously applied mediators of the EAR 
and LAR. However, intrinsic activation of PCLS by stimulation of nerves has not been studied yet. 
Before, in vitro organ bath studies on lung innervation have been performed by EFS on tracheal 
strips, bronchial strips and parenchymal strips; a method that does not allow to access small 
airways, especially when small laboratory animals are used. Parenchymal strips do not allow to 
differentiate between airway and vascular smooth muscle contractions. Furthermore, studies on 
lung tissue in organ baths are performed under either isometric or isotonic conditions, whereas 
the in vivo situation is more auxotonic - as present in PCLS.
Therefore, the aim of the study was to combine the PCLS method with EFS and to establish a 
tool for the examination of peripheral airway innervation. It was the first aim to develop EFS of 
PCLS for one animal species, namely the rat, to specify EFS conditions that specifically activate 
nerves and exclude direct electric ASM stimulation. Neurally-evoked airway responses should be 
addressed pharmacologically to resolve types of innervation in peripheral airways. Since small 
airways respond to exogenous mediators, e.g. methacholine, differently from large airways, airways 
of different size should be addressed in EFS of PCLS.
After establishing the model of EFS of PCLS, lungs from allergic rats should be studieded to prove 
if nerves contribute to a possible AHR. Allergen and methacholine provocation of PCLS should 
also be investigated in the allergic rat model to evaluate a possible EAR and an unspecific AHR, 
respectively.
Finally, EFS of PCLS should be transferred to different species, to characterize their types of 
innervations, i.e. parasympathetic cholinergic, sympathetic adrenergic and/or NANC. The final 
aim was to compare PCLS from animals to those from humans to identify suitable animal models 
that allow predictions for pharmacological interventions.
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3.1 Animals
Harvesting of lungs from laboratory animals was approved by the local ethic committee (reference 
number 8.87-51.05.20.09.245). Balb/c mice (21 - 23 g) were from Harlan Winkelmann (Borchen, 
Germany), Wistar rats (200 - 300 g) from Janvier (Le Genest St. Isle, France) or Harlan Winkelmann 
(Borchen, Germany), Brown Norway rats (180 - 250 g) from Janvier (Le Genest St. Isle, France) 
and Dunkin Hartley guinea pigs (340 - 550 g) from Charles River (Sulzfeld, Germany). Lungs from 
adult marmoset monkeys (Callithrix jacchus) were obtained from the German Primate Center 
(Göttingen, Germany). Sheep lungs were taken from adult Texel sheep kept at the Maastricht 
University Medical Center (Maastricht, Netherlands). Care and housing conditions of the animals 
complied with the regulations of the European Parliament and the Council Directive on the 
protection of animals used for scientific purposes (2010/63/EU) and the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.
3.2 Human material
Human PCLS were prepared from patients undergoing lobectomy due to cancer. After pathological 
inspection, cancer free lung tissue was used. The experiments were approved by the local ethics 
committee and all patients gave written informed consent.
3.3 Chemicals
Acetylcholine, aluminium hydroxide, atropine, bovine serum albumin (BSA), capsaicin, 
4-diphenylacetoxy-N-(2-chloroethyl)piperidine hydrochloride (4-DAMP), ipratropium bromide, 
magnesium sulphate, methacholine, neostigmine, N
ω
-nitro-L-arginine methyl ester (L-NAME), 
OVA grade V (≥ 98% purity), propranolol hydrochloride, Ruthenium red, SKF96365 (1-(β-[3-
(4-methoxyphenyl)propoxy]-4-methoxyphenethyl)-1H-imidazole) and standard laboratory 
chemicals were purchased from Sigma (Steinheim, Germany). Custom Bordetella pertussis 
antigen was supplied by Lee laboratories (Grayson, Georgia, USA). Low-melting agarose 
was delivered by Gerbu (Gaiberg, Germany). Penicillin-streptomycin was obtained from 
Gibco (Darmstadt, Germany). [1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]
methyl]-7-oxabicyclo [2.2.1]hept-2yl]-5-heptenoic acid (SQ29548) and 9,11-dideoxy-9α,11α-
methanoepoxy Prostaglandin F2α (U46619) were provided by Biomol (Hamburg, Germany). 
Substances for cell culture were obtained from PAA laboratories (Cölbe, Germany).
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3.4 Cell culture medium
The cell culture medium always comprised 2 mM CaCl2, 1 mM MgSO4, 5 mM KCl, 116 mM 
NaCl, 1 mM NaH2PO4, 17 mM glucose, 26 mM NaHCO3, 25 mM HEPES (4-(2-hydroxyethyl)-1-
peperazineethanesulfonic acid), 1 mM sodium pyruvate, 2 mM glutamine, amino acids (PAA 
laboratories, M11-002, 1:50), vitamins (PAA laboratories, N11-002, 1:100) and 1% (v/v) penicillin-
streptomycin. During slicing, the medium was not supplemented by pyruvate, glutamine, amino 
acids, vitamins and penicillin-streptomycin.
3.5 Preparation of PCLS
PCLS were prepared as previously described (188; 189) and as depicted exemplarily for the rat in 
Figure 6. Briefly, whole lungs of mouse, rat, guinea pig and marmoset were filled via the trachea 
with low-melting agarose (at 37°C), whereas only separate lobes of sheep and human were filled 
with low-melting agarose via the main bronchus. The agarose concentration was always 1.5% (w/v) 
in cell culture medium, except for mouse and rat (0.75% (w/v)). The filled lung tissue was cooled 
A
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Figure 6:  Preparation  of  precision-cut  lung  slices  (PCLS)  from  rat.  A. After anaesthesia the rat is 
tracheotomized and thoracotomy is performed so that the lung lies collapsed in the thorax. B. Low-melting 
agarose (0.75% (w/v)) is filled into the lung via the trachea and solidified on ice. C. The lung is removed en bloc 
from the animal. D. The lobes of the lung are separated, cut into pieces perpendicular to the tracheobronchial 
tree and tissue cores containing the airway are punched. E. PCLS are cut from the cores by means of a modified 
self build Krumdieck tissue slicer. F. PCLS are taken in culture and are viable for at least 72 h.
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on ice to harden the agarose. Then, tissue cores (10 mm in diameter) with a penetrating airway in 
its center were prepared by a rotating sharpened metal tube. Since the lungs from mice were too 
small for tissue coring, the left and right lung were separately embedded in 3% (w/v) agarose before 
cutting. PCLS were cut perpendicular to the airway by means of a Krumdieck tissue slicer (Alabama 
Research and Development, Munford, Al, USA). PCLS were taken in culture and incubated at 37°C 
and 5% carbon dioxide atmosphere. In order to wash out the agarose and to remove cell debris 
as well as released mediators, the medium was changed every 30 min after PCLS preparation and 
every hour for the next two hours. Thereafter, the medium was changed once daily. Only slices 
with an airway free of agarose, beating cilia and an intact and relaxed ASM layer were used in 
experiments one day after preparation.
3.6 Videomicroscopy
The PCLS under study was placed into a cavity of a standard laboratory 12- or 24-well plate and 
mounted on the stage of an inverted Leica DMIL microscope (Leica Microsystems, Wetzlar, 
Germany). The airway area was then monitored by means of a SensiCam 365KL digital camera 
(Visitron Systems, Munich, Germany) at a frame rate of 0.36 Hz in experiments with EFS and 
0.2 Hz in all other experiments. Camera control and image analysis were achieved by Optimas 6.5 
software (Optimas, Bothell, WA, USA). The airway area before the first stimulation was defined as 
100% initial airway area (IAA) (figure 9 B, C).
3.7 EFS of PCLS
EFS of PCLS were carried out in cavities of standard 12-well plates in a reaction volume of 1 mL cell 
culture medium. The PCLS (10 mm in diameter) were placed between two platinum electrodes 
of 12 mm distance and were weighted down by a Teflon ring (9 mm outer diameter x 6 mm 
inner diameter x 4 mm height) (figure 9 A). The electric field was applied by a HSE Stimulator II 
(Hugo Sachs Electronics, March Hugstetten, Germany), which allowed serial rectangular stimuli. 
The electric stimuli are defined by the basic EFS conditions frequency, pulse duration, current 
amplitude, train width and train rhythm. Their meaning is depicted in figure 7.
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nt Figure 7:  Basic  conditions  of 
electric  field  stimulation  (EFS). 
The electric stimuli are described by 
the basic rhythm (G) = 1/frequency 
(F), pulse duration (B), current (A), 
train width (TW) and train rhythm 
(TR).
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The standard provocation protocol comprised the following setting: train rhythm TR = 60 s, train 
width TW = 2.5 s, frequency F = 50 Hz, pulse duration B = 1 ms and current A = 200 mA (equal to 
40 V). The standard stimulation train lasted 3.3 min. 
3.8 Realization of response curves for the basic EFS conditions
The basic EFS parameters frequency, pulse duration, current and train width (figure 7) were 
systematically examined by stimulating the PCLS repeatedly and modulating only one parameter 
while the others were kept constant at the values noted above (chapter 3.7). Frequency, pulse 
duration, current and train width were examined at 0.4 - 100 Hz, 0.1 - 5 ms, 1 - 200 mA and 
0.5 - 20 s, respectively. Recovery between the repetitive stimulations lasted until the airway had 
relaxed to its initial state (3 - 5 min), except for frequency-response curves in species comparison 
where recovery lasted 1 min.
3.9 Examination of large and small airways in EFS of PCLS
PCLS from rat containing differently sized airways ranging from 3.8 x 103 – 1.2 x 106 µm2 
(0.07 – 1.2 mm in diameter) were stimulated by EFS. The first stimulation train was conducted 
without additive and the second train was carried out in the presence of 10 µM neostigmine given 
15 min in advance.
3.10 Pharmacological interventions
3.10.1 Drugs
Distinct drugs were used to characterize airway innervation in EFS of PCLS and exogenous 
activation of PCLS. The relevance of each drug for neural activation, neural specification or 
receptor signalling is specified in table 4.
3.10.2 Application of magnesium
PCLS were repeatedly stimulated by EFS. The first stimulation train took place without magnesium 
sulphate. After 30 min the second stimulation occurred either in the absence or presence of 
10 mM magnesium sulphate to block neuronal calcium entry. Magnesium sulphate was present 
30 min prior to stimulation. After the last stimulation 10-4 M acetylcholine or methacholine were 
added to examine airway contractility in the presence of 10 mM magnesium sulphate. In the 
experiments on PCLS from rat 10 µM neostigmine was present at all times.
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3.10.3 Characterization of EFS-induced neural airway responses
Cholinergic response: Each PCLS from rat was exposed to three stimulation trains. The first 
stimulation train was carried out in the absence of any additive, the effect of acetylcholine esterase 
inhibition (10 µM neostigmine) was examined in the second train and the role of acetylcholine 
receptors (10 µM atropine) was studied in the third train. All drugs were added 15 min prior to 
stimulation. In all other species than rat, the use of neostigmine as cholinergic response amplifier 
was not required and therefore skipped. Exceptionally in guinea pigs, PCLS were not stimulated 
repeatedly but separate PCLS were activated either in the presence or absence of atropine.
Sympathetic response: This response in EFS of PCLS was proven by the β-blocker propranolol. 
A first stimulation train was performed without propranolol as control and a second followed 
15 min after the installation of 10 µM propranolol.
Substance Function Effect
Acetylcholine Muscarinic receptor agonist ASM contraction
Atropine Muscarinic receptor antagonist Inhibition of ASM contraction
Capsaicin Vanilloid receptor agonist Activation of sensory neurons
4-DAMP Muscarinic receptor antagonist Inhibition of ASM contraction
Ipratropium Muscarinic receptor antagonist Inhibition of ASM contraction
L-NAME NO synthase inhibitor Lack of NO release
Magnesium Competes with Ca2+ at synapse Neuromuscular block
Methacholine Muscarinic receptor agonist ASM contraction
Neostigmine Acetylcholine esterase inhibitor Increased cholinergic stimulation
Propranolol Adrenergic β-receptor antagonist Inhibition of ASM relaxation
Ruthenium red NSCC/TRP channel antagonist Diminished eNANC response
SKF96365 TRP channel antagonist Diminished eNANC response
SQ29548 TP receptor antagonist Reversed U46619 agonistic effect
U46619 TP receptor agonist ASM contraction; Modulation of cholinergic transmission
ASM, airway smooth muscle; 4-DAMP, 4-diphenylacetoxy-N-(2-chloroethyl)piperidine hydrochloride; L-NAME, 
N
ω
-nitro-L-arginine methyl ester; NO, nitric oxide; eNANC, excitatory nonadrenergic noncholinergic nerve; 
NSCC, non-selective cation channel; SKF96365, 1-(β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl)-1H-
imidazole; SQ29548, [1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]
hept-2yl]-5-heptenoic acid; TRP, transient receptor potential channel; U46619, 9,11-dideoxy-9α,11α-methanoepoxy 
Prostaglandin F2α
Table 4: Drugs and their importance
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Excitatory NANC response: The unspecific TRP-channel inhibitors SKF96365 (30 µM) and Ruthenium 
red (10 µM) were used to validate eNANC responses in EFS of PCLS. Control stimulations were 
performed without these inhibitors. SKF96365 or Ruthenium red were allowed to equilibrate 
15 min before the first EFS train was performed.
Inhibitory NANC response: This response in EFS of PCLS was validated by the NO synthase inihibitor 
L-NAME. A first stimulation train was performed without L-NAME as control and a second 
followed 15 min after the installation of 100 µM L-NAME.
3.10.4 Concentration dependent antagonism of anticholinergics
Rat PCLS were exposed to eight consecutive stimulation trains. The first stimulation train was 
carried out in the absence of any additive and from the second train 10 µM neostigmine was 
present throughout the whole experiment. In the third to eighth EFS trains the muscarinic 
antagonist (atropine, ipratropium or 4-DAMP) was increased cumulatively to match concentrations 
of 10-11 – 10-6 M. All newly installed drug concentrations were equilibrated for 15 min prior to 
stimulation.
3.10.5 Effect of the TP receptor antagonist SQ29548
PCLS from rats were repeatedly stimulated by EFS. The first stimulation train occurred at 10 µM 
neostigmine. The second stimulation occurred either in the absence or presence of 10 µM 
SQ29548 to block TP receptors. SQ29548 was applied 15 min prior to stimulation. After the 
second stimulation 10 µM U46619 was added to prove receptor blocking by SQ29548 and to 
verify a priming of acetylcholine release by U46619 in a following third EFS train. Airway responses 
during U46619 application were monitored at a frame rate of 0.1 s-1 for 15 min.
3.11 Exogenous activation of airway responses in PCLS
3.11.1 Application of methacholine
Cumulative concentration-response curves with methacholine were performed on PCLS for 
various purposes. In general, methacholine was maintained at concentrations of 10-8 – 10-4 M each 
for 5 min.
The effect of magnesium on ASM was studied by addition of methacholine in the presence or 
absence of 10 mM magnesium sulphate. PCLS from rat were preincubated with magnesium 
sulphate 30 min before addition of the first methacholine concentration. If EFS was performed at 
10 mM magnesium, afterwards 10-4 M methacholine was added in the magnesium group as in the 
3 Materials and Methods 27
control group to exclude an effect of magnesium on the ASM itself.
AHR was evaluated by provocation of PCLS from OVA sensitized or saline treated rats with 
methacholine (10-8 – 10-4 M).
3.11.2 Application of capsaicin
Excitatory NANC nerves were triggered by application of 10 M capsaicin on the PCLS. The airway 
area was monitored by videomicroscopy to quantify the response.
3.11.3  Application of U46619
The effect of atropine on U46619 evoked ASM contraction was evaluated. Herein, a concentration-
response curve was conducted with U46619 (10-8 – 10-4 M) in the presence or absence of 10 µM 
atropine. Preincubation of atropine occurred for 15 min before addition of the first U46619 
concentration. U46619 was cumulatively added every 5 min.
3.12 Active sensitization of rats
3.12.1 Sensitization protocol
Sensitization of male Brown-Norway rats was approved by the “Landesamt für Natur Umwelt 
und Verbraucherschutz Nordrhein-Westfalen” (TVA-10599G1). The sensitization scheme was in 
accordance to Glaab and colleagues (60) and was performed as depicted in figure 8.
At day 0, rats received a subcutaneous injection of 1 mg OVA in 250 µL saline or saline only 
adsorbed to 20 mg aluminium hydroxide. In some animals 6 x 109 heat-inactivated Bordetella 
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Figure 8:  Acute  sensitization  model  for  rat.  At day 0 animals received ovalbumin (OVA) or saline 
subcutaneously (s.c.). Aluminium hydroxide (Al(OH)
3
) and heat-inactivated Bordetella pertussis (B. pertussis) 
organisms served as adjuvants. Sensitization was boosted at day 7, 14 and 21 by intratracheal (i.tr.) installation of 
OVA/saline. Precision-cut lung slices (PCLS) were prepared on day 22 and measurements were conducted the 
following day. Serum samples were collected at the beginning and end of the sensitization. i.p., intraperitoneal; 
for further please see the text.
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pertussis organisms were administered intraperitoneally as adjuvants. The sensitization was 
boosted by intratracheal application of 100 µL 0.3% (w/v) OVA in saline or saline only on day 7, 
14 and 21. For intratracheal applications the animals were sedated with pentobarbital sodium 
(50 mg/kgbodyweight). Preparation of PCLS was performed on day 22 as described in chapter 3.5. 
Serum samples were collected on day 0 and 22 for the determination of IgE titers. 
3.12.2 EFS of PCLS from sensitized animals
EFS were performed on PCLS from OVA sensitized and control animals. EFS comprised the 
standard stimulation protocol (chapter 3.7) as well as the accomplishment of response curves for 
the frequency, pulse duration, current and train width (chapter 3.8).
3.12.3 Allergen provocation of PCLS from sensitized animals
PCLS from OVA sensitized or saline treated rats were provoked by 0.1% (w/v) OVA and airway area 
was monitored for 20 min each 15 s.
3.12.4 Quantification IgE
IgE levels in serum samples were determined by enzyme linked immunosorbent assay (ELISA) 
according to Glaab and coworkers (60). Briefly, F96 Maxisorp NUNC-Immuno Plate (NUNC, 
Roskilde, Denmark) were coated with a mouse monoclonal antibody against rat IgE (MCA193, 
AbD Serotec, Wiesbaden, Germany) in a concentration of 0.1 µg/well. The plates were incubated 
at room temperature overnight, washed five times with 0.05% (v/v) Tween 20 supplemented 
phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 
pH 7.2; sterile filtered) and blocked with 1% (w/v) BSA in PBS for 1 h. After aspiration of the 
blocking solution and washing, serum samples (diluted in PBS, 0.05% (v/v) Tween 20, 1% (w/v) BSA) 
and standard antibody (rat IgE κ, PRP07A, AbD Serotec, Wiesbaden, Germany) in the range of 
15.625 – 1000 ng/mL were incubated for 1 h. Following an additional washing, 100 µL of peroxidase 
conjugated detection antibody (mouse anti rat κ/λ LC:HRP, MCA1296P, AbD Serotec, Wiesbaden, 
Germany) at a concentration of 0.5 µg/mL was added per well and incubated for 1 h until a further 
washing was performed. Then, 100 µL/well of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
solution were applied and enzymatic substrate conversion was carried out for 15 min in the dark. 
The reaction was stopped by 50 µL/well of 1 M sulphuric acid and absorbance was measured in 
an ELISA plate reader (Genios Tecan, Salzburg, Austria) at 450 nm. Wavelength correction was 
measured at 550 nm to correct for optical imperfections in the plate.
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3.13 Statistics
Non-linear regression, Spearman or Pearson correlation, and statistical analyses were performed 
using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, USA) or JMP 9 (SAS Institute, Cary, NC, 
USA). Homoscedasticity was checked by the Bartlett test. Unpaired data were either compared by 
the Mann-Whitney test or the Steel-Dwass test (if variances were unequal) or by the t-test or the 
Tukey test (if variances were equal). Paired data were analyzed by the paired t-test or linear mixed 
model analysis followed by the Tukey test. The statistical test used is indicated in the legends of the 
table or figures. The half-maximal effective frequencies (EF50) were calculated by four parameter 
logistic regression and compared by the F-test. P<0.05 was always considered significant.
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4.1 EFS of PCLS from rats - Design and Development of EFS setup
4.1.1 Setup and basic conditions
Classic organ bath apparatuses were not applicable for the EFS of PCLS, because PCLS are very thin 
and force development due to bronchoconstriction is small, so that the use of force transducers 
was not practicable. In PCLS, airway responses are typically monitored by videomicroscopy (111).
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Figure 9: Setup for electric field stimulation (EFS) of precision-cut lung slices (PCLS). A. Device: PCLS 
of 10 mm in diameter were placed between two platinum electrodes, which are 12 mm apart. PCLS were 
kept in place by a Teflon ring (9 mm outer diameter x 6 mm inner diameter x 4 mm height). The electric 
field was applied by an electric stimulator connected to the electrodes. The electrodes were placed in a 
standard 12-well plate that was placed on the stage of an inverted microscope to follow bronchoconstriction 
by videomicroscopy. B. Photograph of a PCLS. AW, airway; PA, pulmonary artery; PV, pulmonary vein. 
C. Initial and minimal airway area in response to a single electric stimulation (F = 50 Hz, B = 1 ms, A = 200 mA, 
SD = 2.5 s, at 10 µM neostigmine) is depicted. The airway area was used for quantification.
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A device was designed that allows the EFS of PCLS in a cavity of a standard 12-well plate (figure 9 A). 
Two platinum electrodes were held by a movable plastic carrier that fits exactly into a cavity and 
keeps the electrodes 12 mm apart. The electrodes were connected to a HSE Stimulator II allowing 
serial rectangular pulses. PCLS (10 mm in diameter) were placed between the electrodes, weighted 
down by a Teflon ring (which was figured out to be crucial to that the PCLS does not float and 
to establish tethering forces) and reduction in airway lumen area became apparent after electric 
stimulation (figures 9 C and 10). The bronchoconstriction was reversible, as long as the Teflon ring 
was used (figure 10).
Since the PCLS setup differed in geometry from organ bath studies, the basic EFS conditions 
(frequency, pulse duration, current and train width) were evaluated initially. Airway contractions 
increased in a frequency-dependent manner up to 50 Hz, (figure 11 A) with a half maximal 
response (EF50) at (16.7 ± 4.9) Hz. Bronchoconstriction also became stronger with pulse duration, 
current and train width. A plateau response for pulse duration was reached at pulses ≥ 1 ms 
(figure 11 B). At 200 mA (corresponds to 40 V), the maximal current output of the stimulator, 
airways contracted about 35% (figure 11 C). Maximal ASM contraction occurred if train width 
lasted 10 s or longer (figure 11 D). However, the recovery phase to reach the initial airway area lasted 
longer at TW = 10 s (figure 11 D) and contractions persisted in presence of 10 mM magnesium 
((8.0 ± 3.4)%-IAA at TW = 10 s vs. (1.4 ± 0.6)%-IAA at TW =2.5s; mean ± SD; p = 0.036 in Mann-
Whitney test), suggesting unspecific non-neural stimulation at this train width. As a consequence 
0 1 2 3
80
85
90
95
100
0
20
40
60
80
100
+ Teflon ring
w/o Teflon ring
Time [min]
A
ir
w
ay
 a
re
a 
[%
] Airw
ay area [%
]
Figure 10: Role of  the Teflon ring  in electric field  stimulation evoked bronchoconstriction  in PCLS. 
PCLS were either loosely (right y-axis) placed between the electrodes or weighted down by a Teflon ring (left 
y-axis). The latter approach yielded reversible and reproducible airway responses. Data are shown as mean + SD 
of 6 PCLS from 2 rats in the first group or 10 PCLS from 6 rats in the group with the Teflon ring. EFS conditions 
were F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s and TR = 60 s.
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of these results, it was decided to carry out the following experiments with the Teflon ring in place, 
at a frequency of F = 50 Hz, a pulse duration of B = 1 ms, a current of A = 200 mA and a train 
width of TW = 2.5 s. These conditions resulted in reproducible airway contractions (figure 12).
4.1.2 Cholinergic interventions
To examine the role of cholinergic nerves in the EFS-induced bronchoconstriction, PCLS were 
stimulated in the presence of neostigmine to enhance acetylcholine concentrations in the synaptic 
cleft and atropine to block post-synaptic acetylcholine receptors. In the presence of neostigmine 
(10 µM), EFS contracted airways to (49.2 ± 11.0)%-IAA compared to (84.1 ± 5.3)%-IAA without 
neostigmine (figure 12). With neostigmine still present, atropine nearly completely abolished the 
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Figure 11: Determination of the basic EFS parameters to stimulate PCLS from rat. Except of the parameter 
that was changed in panel A-D, the stimulation settings were always F = 50 Hz, B = 1 ms, A = 200 mA, 
TW = 2.5 s. A. Frequency dependency of airway contraction by EFS. Data are shown as mean ± SD of 11 PCLS 
from 5 rats; EF
50
 = 16.7 ± 4.9 Hz. Effect of pulse duration (B) and current (C) on airway contraction by EFS. 
Data are shown as mean ± SD of 6 PCLS from 6 rats. D. Train width was increased to show maximal airway 
contraction in response to EFS of PCLS. Data are shown as mean ± SD of 6 PCLS from 6 rats.
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EFS-induced airway contractions (figure 12) indicating that airway contractions in rat PCLS mainly 
depend on muscarinic receptors.
After validation of the cholinergic response to EFS, the setup was further developed for the testing 
of anticholinergic drugs. Repeatable EFS of PCLS was reversible and reproducible for at least 
seven consecutive stimulations after neostigmine addition, allowing successive stimulations while 
increasing drug concentrations at the same time (figure 13; for clarity each single spike represents 
the mean train of four times EFS, i.e. the total of eight stimulations mean that 28 EFS trains 
occurred within in each PCLS, underlining the high reproducibility) Atropine, ipratropium and 
4-DAMP showed a concentration-dependent reduction in airway contraction upon EFS. Plotting 
the mean minimal airway area obtained against the logarithmic antagonistic concentration 
revealed sigmoidal inhibition curves with significant different values of half-maximal inhibitory 
concentrations (IC50). Ipratropium with a decadic logarithmic (log) IC50 of (-10.0 ± 0.4) M was more 
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Figure 12: Cholinergic mediation of EFS-triggered airway contraction. The same PCLS was stimulated 
repeatedly (at F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s, TR = 60 s): the entire time course for a single 
experiment with one slice is shown on the abscissa. The time course of airway area in successive EFS trains 
(4 x EFS in 3.3 min) is depicted on the left (A) and the statistical evaluation based on the minimal airway 
area shown as bar graphs on the right (B). The top lane shows the results of EFS without any addition to 
the incubation medium. The middle lane shows the results from EFS experiments in the presence of the 
acetylcholine esterase inhibitor neostigmine (10 µM). The bottom lane shows EFS experiments in the presence 
of neostigmine plus the muscarinic receptor antagonist atropine (10 µM). C, control EFS; N, neostigmine + 
EFS; N + A, neostigmine + atropine + EFS; n.s., not significant; **, p < 0.01; ***, p < 0.001 in the Tukey multiple 
comparison test; data are shown as mean - SD (A) or mean + SD (B) from 5 independent experiments.
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Figure 13:  Increasing concentrations of anticholinergic drugs block airway contractions  in repeated 
EFS  of  PCLS. The same PCLS was stimulated repeatedly at F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s 
and TR = 60 s, i.e. a 1 min interval represents the mean course of 4 x EFS during 3.3 min. Drugs tested were 
added and equilibrated for 15 min prior to the according EFS train. Data are presented as mean - SD of 5 rats. 
A. Neostigmine increased airway contractions were reproducible for at least seven consecutive trains. Atropine 
(B), ipratropium (C) and 4-DAMP (D) were cumulatively add in consecutive EFS trains to match indicated 
concentrations (10-11 M - 10-6 M). In B-D like in A, neostigmine was present throughout the whole experiment 
beginning from the second EFS train.
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potent to block airway response than atropine or 4-DAMP which showed equal log IC50 values of 
(-8.8 ± 0.4) M and (-8.4 ± 0.3) M respectively (figure 14).
4.1.3 Effect of magnesium to prove neural activation
The effects of magnesium concentrations high enough to block voltage-gated calcium entry in 
neuronal cells (40; 53) were examined to verify that the EFS evoked airway contractions were 
due to neural stimulation. 10 mM magnesium sulphate totally abolished the EFS-induced 
contractions in the presence of 10 µM neostigmine (figure 15 A-C). In contrast, airway contraction 
by exogenously added acetylcholine was not affected by magnesium sulphate (figure 15 A-C) and 
10 mM magnesium sulphate did not alter the concentration-response curve of methacholine-
induced bronchoconstriction (figure 15 D).
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Figure 14: Ipratropium is more potent to block EFS evoked bronchoconstriction in PCLS than atropine 
or 4-DAMP. The mean minimal airway areas obtained in figure 13 are plotted against the decadic logarithmic 
(log) concentration of atropine, ipratropium or 4-DAMP. Curves were compared by performing extra sum-of-
square F-test on top, bottom, slope and half-maximal inhibitory concentration (IC
50
). Significant differences 
at an α-level of *, p < 0.05 and **, p < 0.01 were found for the log IC
50
 values of ipratropium and atropine or 
4-DAMP, respectively; data are shown as mean ± SEM (n = 5) in the graph and mean ± SD in the curve analysis 
table.
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Figure 15: Effect of magnesium on airway contractions by EFS and acetylcholine derivatives. A. First 
and second train: 4 x EFS (F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s, TR = 60 s) in 3.3 min in the presence 
of 10 µM neostigmine; third train: addition of 100 µM acetylcholine; n = 6. The entire time course for a single 
experiment with one slice is shown on the abscissa. B. The same experiments as in panel A with the addition 
of 10 mM MgSO
4
 30 min prior to the second train; n = 5. C. Summary of the minimal airway area obtained 
in the experiments shown in panel A and B as bar chart. EFS, electric field stimulation; ex. ACh, exogenous 
acetylcholine; n.s., not significant in t-test of selected pair of columns; **, p < 0.01 in Mann-Whitney test of 
selected pair of columns; data are shown as mean - SD (A, B) or mean + SD (C). D. Cumulative concentration- 
response curves of methacholine-induced airway contraction in PCLS were recorded in the absence or 
presence of 10 mM MgSO
4
. MgSO
4
 was added 30 min before the first addition of methacholine. Data are 
shown as mean ± SD of 8 PCLS for each condition from 5 animals. A shared concentration-response curve was 
suitable to fit the data, because there was no statistical difference at p < 0.05 (F-test) in any parameter of the 
4-parameter logistic equation between the two data sets.
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4.1.4 Response of different airway sizes
Since small airways respond stronger to methacholine than larger ones (111), the response of small 
and large airways were analyzed to EFS (figure 16).
EFS were studied in PCLS with airway sizes ranging from 3.8 x 103 - 1.2 x 106 µm2 in the presence or 
absence of neostigmine. Herein, larger airways were more responsive than smaller ones (figure 16). 
Additionally, the amplification of airway contraction by neostigmine was more pronounced in 
larger airways.
4.1.5 TP receptor involvement
An interaction between TP receptor signalling and parasympathetic cholinergic acetylcholine 
release has been shown for dogs, guinea pigs and mice (4; 7; 167; 176), whereas this mechanism 
has not yet been characterized in rat lungs. Therefore, the influence of the TP receptor antagonist 
SQ29548 was studied in EFS of rat PCLS. No difference was found for electrically evoked cholinergic 
airway responses in the presence and absence of a TP receptor antagonist (figure 17). A statistical 
power calculation based on these results (figure 17 C) indicated that at least 32 experiments were 
needed to possibly reach significance, indicating that any role of TP receptors would be rather 
small.
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Figure 16: Correlation of airway size with EFS-triggered airway contractions. PCLS were first stimulated 
in the absence (○) and then in the presence (●) of 10 µM neostigmine, i.e. the data are paired. Rat airway 
generations are marked on the upper x-axis according to Yeh and colleagues (191). A one phase exponential-
decay described the relationship reasonably well. R2, goodness of fit; data show the results of 29 PCLS from 
5 rats.
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The addition of U46619 demonstrated that SQ29548 was capable of blocking TP receptors in the 
present system (figure 17 D). Moreover, a subsequent EFS train in the presence of U46619 did not 
increase the response (figure 18).
0
20
40
60
80
100
120
EFS EFS ex. U46619
A
ir
w
ay
 a
re
a 
[%
-IA
A
]
0 1 2 3
0
20
40
60
80
100
120
18 19 20 21 22 27 32 37
10 µM SQ29548 10 µM SQ29548
Time [min]
A
ir
w
ay
 a
re
a 
[%
-IA
A
]
- SQ + SQ
0
20
40
60
80 n.s.
M
in
im
al
 a
irw
ay
 a
re
a 
[%
-IA
A
]
- SQ + SQ
0
20
40
60
80
100
120
*
A
irw
ay
 a
re
a 
[%
-IA
A
]
(t
 =
 1
5 
m
in
 p
os
t 
U
46
61
9)
A
B
C D
Figure 17:  Effect  of  the  thromboxane  prostanoid  (TP)  receptor  antagonist  SQ29548  on  broncho-
constriction induced by EFS or U46619. A. First and second train: 4 x EFS (F = 50 Hz, B = 1 ms, A = 200 mA, 
TW = 2.5 s, TR = 60 s) in 3.3 min in the presence of 10 µM neostigmine; third train: addition of 10 µM of the 
TP receptor agonist U46619; n = 4. The entire time course for a single experiment with one slice is shown on 
the abscissa. B. The same experiments as in panel A with the addition of 10 µM SQ29548 15 min prior to the 
second train; n = 5. C. Bar graph summary of the minimal airway area obtained in the EFS trains in panel A 
and B; n.s., not significant in t-test. D. Bar graph summary of the airway area obtained 15 min after U46619 
addition in panel A and B; *, p < 0.05 in Mann-Whitney test. EFS, electric field stimulation; ex. U46619, exogenous 
U46619; data are shown as mean - SD (A, B) or mean + SD (C, D).
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The influence of TP receptor agonist U46619 and its possible interactions with muscarinic receptors 
was studied by the use of atropine. The airway responses for cumulative concentration-response 
curves with U46619 were the same in the presence and absence of atropine (figure 19).
4.2 Active sensitization of rats
In the foregoing part, the EFS of PCLS was established in healthy rats. Now this method was used 
to study the neurally-induced bronchoconstriction of peripheral airways within an experimental 
rat model of asthma, since nerves may exhibit enhanced reflex activity, increased mediator release, 
increased receptor-density or quantitative changes during asthma (143). The ASM itself may also 
display enhanced sensitivity to neuropeptides and tachykinins or posses an increased receptor 
density (143). The sensitization occurred according to Glaab and colleagues (60), who observed 
an AHR in vivo and an increased number of immune cells (eosinophils, lymphocytes, neutrophils 
and macrophages) in brochoalveolar lavage of OVA sensitized animals. Herein, OVA adsorbed 
to aluminium hydroxide was injected subcutaneously, and some animals also received heat-
inactivated Bordetella pertussis, to initiate an intended TH2-lymphocyte driven immune response. 
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Figure 18: U46619 does not prime the airway 
response  to  EFS. A subsequent EFS train was 
carried out on the same set of PCLS as depicted 
in figure 17. For both groups (± 10 µM SQ29548) 
no significant (n.s.) difference was found before 
(open symbols) and after (closed symbols) 
addition of U46619 (10 µM) in the Tukey 
multiple comparison test.
Figure 19:  Effect  of  atropine  on  airway 
contraction  by  U46619. Cumulative con-
centration response curves of the U46619-
induced airway contraction in PCLS were 
recorded in the absence or presence of 10 µM 
atropine. Atropine was added 15 min before 
the first addition of U46619. Data are shown as 
mean ± SEM of 9 PCLS for each condition. A 
total of 5 animals were used for the experiment. 
A shared concentration-response curve was 
suitable to fit the data, because there was no 
statistical difference at p < 0.05 (F-test) in any 
parameter of the 4-parameter logistic equation 
between the two data sets.
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In order to boost the immune response repeated challenges with allergen were performed 
intatracheally assuring its deposition in the lung.
4.2.1 Macroscopic observations
During active sensitization, rats were either repeatedly challenged by OVA (sensitized group) or 
saline (control group) for three weeks.  Neither control nor sensitized animals showed wheezing 
A B
C D
FE
Figure 20: Ovalbumin  (OVA)  sensitized  rats  showed haemorrhages  throughout  the  lung. Rats were 
actively sensitized to OVA (B, D, F) or received saline in the control group (A, C, E) as described in chapter 
3.12.1. A, B. The lung lied collapsed in the thorax after thoracotomy. C, D. The agarose filled lung was removed 
en bloc from the animal. E, F. PCLS were taken in culture. White arrows indicate haemorrhages.
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while sensitization and none of the animals appeared to be heavily sick. When rats were taken 
for preparation of PCLS, haemorrhages on the surface of the lung became apparent in the 
sensitized animals after thoracotomy, whereas in control animals haemorrhages were not present 
(figure 20 A-D). Haemorrhages in sensitized rat were spread throughout the whole lung and were 
still found in PCLS after the cutting process (figure 20 E, F).
4.2.2 Response of PCLS to allergen provocation
To demonstrate a response to allergen after active sensitization, PCLS were provoked with 
0.1% (w/v) OVA for 20 min and airway area was monitored. Only rats from OVA sensitzed rats 
responded with a moderate airway contraction (figure 21 A).
Although a significant difference was found between the sensitized and control group, it is 
remarkable that some OVA sensitized rats exhibited very weak if any airway contraction at all 
upon OVA (figure 21 B).
4.2.3 Response of PCLS to methacholine
Methacholine was applied to study an AHR in sensitized animals. The same concentration-
response curve was found for both sensitized and control animals (figure 22), i.e. sensitivity (shared 
EC50) and maximal contraction (shared bottom) to methacholine were the same, and sensitized 
animals were not hyperresponsive.
0 5 10 15 20
80
90
100
Control
Sensitized
Time [min]
A
ir
w
ay
 a
re
a 
[%
-IA
A
]
Control Sensitized
60
80
100
**
M
in
im
al
 a
irw
ay
 a
re
a 
[%
-IA
A
]
A B
Figure 21: Allergen provocation induces bronchoconstriction in sensitzed rat. Rats were actively sensitized 
to ovalbumin (OVA) or received saline in the control group as described in chapter 3.12.1. Provocation of PCLS 
was performed by application of 0.1% (w/v) OVA for 20 min. Groups were not further subdivided by Bordetella 
pertussis application, since the adjuvants did not show an effect. A. The course of airway behaviour is drawn 
after application of allergen. B. Maximal observed airway narrowing differed in sensitized and control group. 
Data are shown as mean ± SEM (n = 6, control; n = 7, sensitized); **, p < 0.01 in Mann-Whitney test.
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4.2.4 IgE levels in sensitization
During sensitization B-lymphocytes produce specific IgE. Therefore, the IgE levels were determined 
to evaluate if sensitization with OVA induced the expression of IgE. Moreover, some animals 
received heat inactivated Bordetella pertussis organisms - a common adjuvants to trigger TH2-cell 
response and in further consequence the production of IgE. In line with this, rats, which received 
Bordetella pertussis as adjuvants, had elevated IgE levels three weeks after sensitization in both 
OVA and saline treated animals (figure 23). However, OVA alone had no effect on the titers of 
-8 -7 -6 -5 -4
0
20
40
60
80
100
Control
Sensitized
Shared fit
Methacholine [log M]
A
ir
w
ay
 a
re
a 
[%
-IA
A
]
Figure 22: Sensitized animals are not hyperresponsive to methacholine. Rats were actively sensitized to 
ovalbumin or received saline in the control group as described in chapter 3.12.1. Cumulative concentration- 
response curves of methacholine were performed on PCLS from sensitized or control animals. Groups were 
not further subdivided by Bordetella pertussis application, since the adjuvants did not show an effect. Data are 
shown as mean ± SEM of n = 7 animals in sensitized group and n = 6 in control group. A shared concentration-
response curve was suitable to fit the data, because there was no statistical difference at p < 0.05 in any 
parameter of the 4-parameter logistic equation between the two data sets.
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Figure 23: IgE levels after sensitization. Rats were actively sensitized to ovalbumin or received saline in the 
control group as described in chapter 3.12.1. Some animals also received heat inactivated Bordetella pertussis 
(B. pertussis) organisms as adjuvants at day 0 of sensitization. Data are shown as mean + SD. Groups not 
indicated by the same letter are significantly different according to the Tukey multiple comparison test. +, rats 
received treatment; -, rats did not receive treatment.
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IgE past sensitization (figure 23). Notably, the anti-IgE antibody used in the underlying ELISA only 
detected total IgE but not anti-OVA specific IgE.
4.2.5 Response of PCLS to EFS
Frequency, pulse duration, current and train width are the basic parameters by which the electric 
field can be determined. Nerves are differentially activated by changes in the electric field and 
airway responses are altered. Bronchoconstriction occurred with an increase in each parameter. 
A shared frequency-response curve with an EF50 of (18.9 ± 3.2) Hz was found for OVA sensitized 
and saline control animals (figure 24 A). Furthermore, no significant differences were observed in 
response to increasing pulse durations or train widths for both groups (figure 24 B, D). However, 
the sensitized animals seemed to be less reactive. This was most prominent for the sensitivity to 
increasing currents (figure 24 C).
Deriving from the study of the basic parameters above, one can conclude, that the standard 
stimulation parameters (F = 50 Hz, B = 1 ms, A =200 mA, TW = 2.5 s) as determined during the 
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Figure 24: Response of  PCLS  from  sensitized  and non-sensitized  rats  to basic  EFS parameters. Rats 
were actively sensitized to ovalbumin or received saline in the control group as described in chapter 3.12.1. 
Except of the parameter that was changed in panel A-D, the stimulation settings were always F = 50 Hz, 
B = 1 ms, A = 200 mA, TW = 2.5 s. A. The frequency-response curve resulted in a shared curve with an EF
50
 of 
(18.9 ± 3.2) Hz. B, C and D show the effect of pulse duration, current and train width, respectively, on airway 
contraction in EFS of PCLS from actively sensitized or control animals. Data are allways shown as mean ± SD 
(n = 7, sensitized group, n = 6 control group); *, p < 0.05 in unpaired t-test on the area under the curve.
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development of EFS (chapter 4.1.1) are also appropriate here when examining sensitized and non-
sensitized rats. Therefore, the responses of PCLS from either sensitized or saline treated rats were 
exposed to the standard stimulation conditions. Interestingly, a significant difference was figured 
out in which PCLS from the OVA treated rats were less reactive (figure 25), even though the small 
difference may not be physiologically relevant.
Since there was the probability that not all rats were effectively sensitized the airway response to 
standard EFS of PCLS from both control and OVA treated group was plotted against their response 
to allergen provocation. However, Spearman analysis did not result in any correlation (figure 26).
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Figure 25: Response of PCLS from sensitized and 
non-sensitized rats to standard EFS conditions. 
Rats were actively sensitized to ovalbumin or 
received saline in the control group as described 
in chapter 3.12.1. EFS was carried out at F = 50 Hz, 
B = 1 ms, A = 200 mA and TW = 2.5 s. Data are 
shown as mean + SEM of 47 PCLS from 7 sensitized 
rats and 43 PCLS from 6 saline control rats;
*, p < 0.05 in unpaired t-test.
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Figure 26: There  is  no  correlation between  air-
way responses to EFS and response to ovalbumin 
(OVA). The mean ± SD response to standard EFS 
(F = 50 Hz, B = 1 ms, A = 200 mA and TW = 2.5 s) 
of each rat out of the sensitization experiment 
(chapter 3.12.1), i.e. sensitized and control rats are 
combined and each data point reflects a single 
animal, is depicted against the according response to 
OVA provocation (figure 21). Spearman correlation 
resulted in r = -0.052 pointing to an insignificant 
correlation.
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] Figure 27: Airway response to EFS  is correlated 
to  the  IgE  titer.  The mean ± SD response to 
standard EFS (F = 50 Hz, B = 1 ms, A = 200 mA 
and TW = 2.5 s) of each rat out of the sensitization 
experiment (chapter 3.12.1), i.e. sensitized and 
control rats are combined and each data point 
reflects a single animal, is depicted against the 
IgE level obtained after 3 weeks of sensitization 
(figure 23). Pearson correlation resulted in significant 
correlation (r = 0.636, p = 0.019), and consequently a 
linear regression was conducted.
4 Results 45
Moreover, as the IgE level is indicative of the immune status of the animal, the airway response to 
EFS of PCLS from both control and OVA treated rats was correlated to the IgE levels (figure 27). 
Pearson analysis resulted in a significant dependence (r = 0.636, p = 0.019). As Pearson correlation 
assumes a linear dependence, a linear regression was performed showing lesser reactivity with 
higher IgE titer (figure 27).
4.3 Species comparison
4.3.1 Responses and sensitivity to EFS
PCLS from the various species responded differently to EFS; please note the different scales in 
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Figure 28:  Airway  response  of  PCLS  from  distinct  species  to  EFS.  PCLS from indicated species were 
stimulated repeatedly at F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s, TR = 60 s for 3.3 min, i.e. each PCLS 
received 4 x EFS. A. The time course of airway area in successive EFS trains is depicted as mean – SD for each 
species. The statistical evaluation based on the minimal (B) and maximal airway area (C) is shown as Box and 
Whiskers plots. Groups not indicated by the same letter are significantly different at p < 0.05 according to the 
Steel-Dwass comparison test.
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figure 28. Airways from mice did not respond in the range of the EFS conditions studied here 
even in the presence of neostigmine (Minimal airway area: (98.2 ± 0.9)%-IAA (control) vs. 
(94.3 ± 2.2)%-IAA (neostigmine); mean ± SEM; n = 4; p = 0.1581 in t-test). However, the application 
of substantially higher frequencies or pulse durations led to airway contractions also in mouse 
PCLS, which were blocked by magnesium indicating neural origin (figure 29). PCLS from rats 
and marmoset contracted reversibly by about 20% (figure 28 A, B). Airways in PCLS from guinea 
pigs, sheep and human contracted strongest by about 40%-IAA – 60%-IAA and did not revert 
to the initial area during the one minute interval until the next electric impulse was applied 
(figure 28 A, B). Marmoset airways showed a unique behaviour in that contraction was followed 
by relaxation that exceeded the original airway caliber ((116 ± 18)%-IAA; figure 28 C).
Analyzing the frequency-response curves (figure 30) revealed the following order of species 
sensitivity to EFS: sheep (EF50 = (0.5 ± 0.2) Hz) > guinea pig (EF50 = (7.0 ± 1.2) Hz) = human 
(EF50 = (8.1 ± 0.8) Hz) > rat (EF50 = (16.5 ± 0.8) Hz). The EF50 values for humans and guinea pigs did 
not differ statistically. The EF50 of marmoset was (22.8 ± 7.1) Hz but the frequency-response curve 
neglects the relaxant response and therefore the EF50 appears higher than without relaxation.
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Figure 29:  Electrically  activated  airway  contractions  in  murine  PCLS  require  higher  electric  fields 
and remain neuronally-induced. A. Frequency-response curve: The frequency (F) was increased from 1 Hz 
to 200 Hz, while the other EFS settings were kept constant at B = 1 ms/2ms, A = 200 mA and TW = 2.5 s. 
B. Pulse duration was increased in EFS of murine PCLS from 0.5 ms to 4 ms, while the other parameters were 
kept constant at F = 50 Hz, A = 200 mA and TW = 2.5 s. C. PCLS from mouse were stimulated repeatedly at 
F = 50 Hz, B = 2 ms A = 200 mA and TW = 2.5 s each minute for 3.3 min. Upper panel: Control stimulations, 
each EFS train was conducted without pharmacological interference. Lower panel: 10 mM magnesium (Mg2+) 
was added 30 min prior to the second EFS train. Magnesium was able to block airway responses indicating 
specific neurally-induced bronchoconstriction. Data are shown as mean ± SD.
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4.3.2 Evidence for neural activation
Magnesium competes at neural calcium channels (N-type calcium channels) and thus prevents 
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Species
EFS Methacholine
Change in airway area [%-IAA] Minimal airway area [%-IAA]
w/o Mg2+ 10 mM Mg2+ w/o Mg2+ 10 mM Mg2+
Rat 19.0 ± 8.8 1.4 ± 0.6 ** 13.5 ± 15.1 30.0 ± 11.5
Guinea Pig 44.3 ± 37.5 3.9 ± 4.1 * 0.0 ± 0.0 7.3 ± 8.5
Sheep 54.4 ± 22.5 7.6 ± 8.3 ## 10.1 ± 10.7 18.4 ± 20.0
Marmoset
(Con./Rel.)
46.0 ± 20.9
(28 ± 27 / 18 ± 20)
13.2 ± 9.0 ##
(11 ± 11 / 2 ± 3) 39.0 ± 25.3 38.2 ± 16.1
Human 36.8 ± 23.1 18.9 ± 19.0 † 32.2 ± 23.2 35.4 ± 20.2
Magnesium competes with calcium at the terminal synapse and prevents the release of neurotransmitters 
resulting in a neuromuscular block (40; 53). The muscarinic receptor agonist methacholine was used 
to confirm that Mg2+ did not affect airway smooth muscle directly. Con., contraction; EFS; electric 
field stimulation; IAA, initial airway area; Mg2+, magnesium; Rel., relaxation; w/o, without; *, p < 0.05; 
**, p < 0.01 in Mann-Whitney test; ##, p < 0.01 in t-test; †, p < 0.05 in paired t-test.
Table 5: EFS-induced airway contractions are neurally mediated.
Figure 30:  Frequency dependence  across  species. Frequency-response curves were performed on PCLS 
from the species indicated. Except for the frequency (F), which was increased from 0.4 Hz to 100 Hz after a 
single train at the distinct frequency each minute (TR = 60 s), EFS settings were kept constant at B = 1 ms, 
A = 200 mA and TW = 2.5 s. Sigmoidal curves, in which the top was constrained to 100% of the initial 
airway area [IAA], were plotted and frequencies for the half-maximal response (EF
50
) were determined: rat 
(16.5 ± 0.8) Hz, guinea pig (7.0 ± 1.2) Hz, sheep (0.5 ± 0.2) Hz, marmoset (22.8 ± 7.1) Hz, human (8.1 ± 0.8) Hz. 
Except for the guinea pig, EF
50
 values from all species were significantly different from the human EF
50
. Data 
are shown as mean ± SEM; n = 6 for rat, n = 5 for guinea pig, n = 4 for sheep, n = 4 for marmoset and n = 4 
for human.
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neural responses, but not those acting directly on smooth muscle cells (40; 53). EFS performed 
in the presence of 10 mM magnesium inhibited airway reactions in all species, but did not alter 
responses to exogenously added methacholine (table 5) demonstrating that the EFS-induced 
responses depended on neural transmission in all species.
4.3.3 Cholinergic antagonism
The muscarinic antagonist atropine significantly reduced airway contraction in repeated EFS of rat, 
sheep, marmoset and human PCLS (figure 31). Of note, in the case of rat PCLS the acetylcholine 
esterase inhibitor neostigimine was used to augment the response.  In guinea pigs, PCLS had to 
be pre-incubated with atropine before the first stimulation in order to demonstrate cholinergic 
airway innervation (figure 33 C, D).
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Figure 31: Cholinergic responses in EFS-triggered airway contraction. PCLS from either rats (A), sheep 
(B), marmosets (C) or human (D) were stimulated repeatedly at F = 50 Hz, B = 1 ms, A = 200 mA, TW = 2.5 s, 
TR = 60 s for 3.3 min, i.e. 4 x EFS. As control, the first stimulation (1st EFS) was always carried out without 
any cholinergic interference. In subsequent EFS separated by at least 15 min to the preceding stimulation, 
neostigmine and/or atropine were added to augment or inhibit, respectively, cholinergic airway contraction. 
*, p < 0.05 and **, p < 0.01 for atropine vs. no atropine (paired t-test). The guinea pig data are shown in figure 33.
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4.3.4 Activation by capsaicin
Neurally triggered airway contraction may not be restricted to cholinergic innervation but can 
also be due to eNANC innervation. Therefore, the effect of capsaicin was studied.
Capsaicin induced strong airway contractions in PCLS from guinea pigs and moderate contractions 
in human PCLS (figure 32); of note, two out of five human lungs did not respond to capsaicin. In 
mouse, rat, sheep and marmoset capsaicin did not affect airway tone (figure 32).
4.3.5 Role of TRP-channels in neurally evoked bronchoconstriction
To further characterize the strong response to capsaicin in guinea pigs, PCLS were incubated with 
the unspecific TRP-channel blockers SKF96365 or Ruthenium red before stimulation by capsaicin. 
Both inhibitors significantly reduced the response to capsaicin (figure 33). Since in guinea pigs 
airways did not relax back to the initial airway area after an EFS (figure 28), even if recovery periods 
were prolonged, a non-cholinergic mechanism appeared likely. This was studied by the application 
of Ruthenium red and SKF96365 during EFS of guinea pig PCLS. As PCLS could not be stimulated 
repeatedly due to the lack of relaxation, PCLS were grouped and incubated with the inhibitors prior 
to the first stimulation. Atropine, Ruthenium red and SKF96365 were all effective in blocking the 
response compared to the control group, although they failed to abolish the response completely 
(figure 33).
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Figure 32: Effect of capsaicin on airway contraction  in PCLS. Capsaicin was applied to PCLS from the 
species indicated at a concentration of 10 µM and airway contraction was monitored. Data are shown as 
mean – SEM; n = 3 for mouse, n = 10 for rat, n = 9 for guinea pig, n = 4 for sheep, n = 3 for marmoset and 
n = 5 for human.
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4.3.6 Effect of propranolol and L-NAME in EFS of PCLS from marmoset
As noted above, in marmosets the airway caliber enlarged following electric stimulation suggesting 
adrenergic or iNANC responses. To examine their contributions, EFS was performed subsequently 
to a control train in the presence of the β-blocker propranolol, the NO synthase inhibitor L-NAME or 
both together. Each antagonist alone was unable to significantly reduce the relaxant response, but 
the combination of both was effective (figure 34). Figure 34 suggests that propranolol alone might 
also have been effective; however the statistical power was probably not sufficient; a statistical 
Figure 33: Characterization of peripheral  airway  innervation  in guinea pigs. A. Capsaicin was added 
to precision-cut lung slices (PCLS) at a concentration of 10 µM, either after 15 min pre-incubation with 
an unspecific transient receptor potential (TRP) channel blocker (Ruthenium red, SKF96365) or without 
pre-incubation (control). Data are shown as mean – SEM; n = 5. 100% of the initial airway area (IAA) was 
considered as baseline and the area above the curve (AAC), i.e., the area enclosed by the baseline and the curve, 
is depicted as shading. B. Statistical analysis was performed on the AAC calculated from panel A. Data are 
shown as mean + SEM; n = 5; *, p < 0.05 in linear mixed model analysis followed by the Tukey test. C. Electric 
field stimulation (EFS; F = 50 Hz, B = 1 ms, A = 200 mA, SD = 2.5 s) was carried out on PCLS either after pre-
incubation with TRP channel blockers, the muscarinic inhibitor atropine or without pre-treatment (control) 
and the airway responses are depicted as mean – SEM; n = 5 - 6. D. The minimal airway area obtained in the 
EFS of PCLS was used in statistical analysis showing an effect for all antagonists. Data are shown as mean + SEM; 
n = 5 - 6; *, p < 0.05 and **, p < 0.01 for the comparison to the control group in the Tukey multiple comparison 
test.
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power analysis suggested that 9 independent experiments might be required to achieve statistical 
significance. However, as marmosets are non-human primates and in order to save animals, we 
refrained from further experiments to clarify this issue. Regarding L-NAME it is remarkable, that in 
its presence airway recovery to baseline values was prevented (figure 34 C, 2nd train), suggesting a 
role of NO in this process.
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Figure 34:  Airway  relaxation  in  marmosets  is  due  to  adrenergic  and  inhibitory  nonadrenergic 
noncholinergic  (iNANC)  innervation. The same PCLS was stimulated repeatedly (F = 50 Hz, B = 1 ms, 
A = 200 mA, TW = 2.5 s, TR = 60 s): the entire time course for a single experiment with one PCLS is shown on 
the abscissa. The time course of airway area in successive EFS trains (4 x EFS in 3.3 min) is depicted on the left 
and the statistical evaluation based on the difference between the maximal and minimal airway area (Δ-airway 
area) during the respective train is shown as bar graphs on the right. A. The results of EFS without any addition 
to the incubation medium. B. The results from EFS experiments in the presence of the adrenergic β-blocker 
propranolol. C. The results from EFS experiments in the presence of the NO synthase inhibitor L-NAME. 
D. The results from EFS experiments in the presence of the combination of propranolol and L-NAME. Data are 
shown as mean - SD (left) or mean + SD (right); *, p < 0.05 in one-tailed paired t-test.
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5 Discussion
Application of an electric field to PCLS resulted in airway contractions that were inhibited by 
magnesium. Therefore, in PCLS bronchoconstriction triggered by EFS is neurally induced implying 
that nerve endings remain intact in PCLS. In rats, neural responses are mainly cholinergic and 
decrease with decreasing airway size. PCLS from allergic rats were neither hyperresponsive to 
EFS nor to methacholine indicating that increased release of acetylcholine from postganglionic 
parasympathetic nerves does not occur and that acetylcholine receptors and the postreceptor 
transduction mechanisms are not affected by allergen exposure in rat. Finally, the EFS was adopted 
for PCLS from mice, guinea pigs, sheep, marmosets and humans. Cholinergic airway responses 
were found for guinea pigs, sheep, marmosets and humans. Furthermore, guinea pig and human 
PCLS were activated by capsaicin showing eNANC responses. The EFS-induced airway dilation in 
PCLS from marmosets was blocked by propranolol and L-NAME pointing to iNANC nerves in this 
species.
5.1 Design and development of EFS-setup on the basis of rat PCLS
Viable PCLS have been established as a useful tool to study airway tone, pulmonary vascular 
responses, ciliary beating as well as immunological and toxicological properties of the lung 
(34; 68; 111; 112; 188; 189). This study established neural stimulation of PCLS. EFS-induced 
bronchoconstriction is consistent, reproducible, sensitive to anticholinergics and enhanced by 
an acetylcholine esterase inhibitor in rats. Ipratropium was more potent to block EFS-induced 
cholinergic airway contraction than atropine or 4-DAMP. The effect of the EFS was strongest in 
the larger airways and appeared to be mediated by synaptic release of acetylcholine. This model 
will useful to further study mechanisms of neural airway control and cholinergic AHR in rats and 
other species.
5.1.1 General EFS-setup in PCLS
The extent of the EFS-induced contractions of 15%-IAA in large airways roughly corresponds to 
contractions elicited by 330 nM of the metabolically stable acetylcholine derivative methacholine 
(figure 8 B in (111)), suggesting that this may be the effective acetylcholine-concentration in the 
synaptic cleft following presynaptic discharge. These findings indicate that neurally-induced 
bronchoconstriction can regulate airway tone, but is unlikely to lead to complete airway closure as 
shown for instance for allergen provocation (189). Comparing the present findings to other studies 
it should be noted that the data were not normalized to contractions induced for example by KCl, 
a procedure which may overstate the real magnitude of the effects. Normalization to receptor 
agonists (e.g. methacholine) was omitted throughout the study as it has been previously shown 
that responsiveness of small airways is stronger to methacholine and other stimuli (111; 112; 188; 
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189). In such a situation, normalization would distort the results. The EFS-induced contraction 
by approximately 15%-IAA was strongly potentiated by inhibition of the acetylcholine esterase 
(figure 12). These findings indicate that in PCLS cholinergic synapses remain intact, as they respond 
to electrical currents, possess active acetylcholine esterase (see experiments with neostigmine) 
and acetylcholine-receptors (see experiments with atropine) and recycle acetylcholine in a normal 
fashion (otherwise repetitive stimulations would not have been possible).
EFS was applied to stimulate neuronal cells, but, depending on the frequency and duration of 
the electric stimulus, direct contraction of smooth muscle cells may also occur (45). To exclude 
such an unspecific direct stimulation of voltage-gated channels on ASM, the effect of magnesium 
was examined. At high concentrations, magnesium prevents voltage-induced calcium entry 
and thereby the release of neurotransmitters from nerve terminals (40; 53). Since magnesium 
completely prevented the bronchoconstriction induced by EFS, but not by methacholine, it is 
concluded that in the present setup the EFS acts only on nerve endings and not on ASM (figure 15).
5.1.2 Relevance of the basic EFS conditions
For organ bath experiments, Wang and colleagues (183) systematically studied the influence of 
pulse duration (0.5 - 3 ms), muscle preload (2 - 20 g), voltage (5 - 20 V) and frequency (0.5 - 16 Hz) 
on the release of acetylcholine from equine airway cholinergic nerves, in order to provide guidelines 
for selecting EFS parameters in future studies. As they observed an increasing acetylcholine release 
from 2.1 – 18.6 pmol/gtissue-wet-weight/min with increasing frequencies (2 – 16 Hz), frequencies were 
analyzed in the present study by steadily increasing them while the other stimulation parameters 
were kept constant. This resulted in a sigmoidal frequency-response curve for the airway area 
change (figure 11 A) plateauing at F = 50 Hz, somewhat above the frequency observed by Wang 
and colleagues (183) (> 8 Hz). The most likely explanation for these differences is interspecies 
variability, as PCLS from other species (e.g. sheep) responded already at lower frequencies (figure 30) 
and our EF50 of (16.7 ± 4.9) Hz is almost identical to the (19.3 ± 4.3) Hz reported by Gonzalez and 
Santana (61) on isometric tension studies of rat tracheal smooth muscle. In addition they also 
found a plateau phase above 40 Hz (61), whereas the EF50 of 4.4 Hz in Wang’s and colleagues’ (183) 
study of horse airways was markedly lower. To put these figures into proportion, the maximal 
frequency that allows motoneurons to depolarize during repetitive stimulation is 500 - 1000 Hz 
(84). It should also be noted that Mitchell and colleagues (119) showed relatively high frequencies of 
action potentials (peak frequency of 10 - 13 Hz) for feline tracheal parasympathetic ganglion cells 
during normal breathing. Also other factors such as electrode geometry and the ionic strength of 
our cell culture medium have to be taken into account, as the inner electric field strength depends 
on the conductivity of the medium and on the current density, which in turn depends on a shape 
factor, the frequency and the external electric field strength. Taken together, the frequencies that 
were applied in rat PCLS appear reasonable.
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With respect to pulse duration it was found, similar to Wang and colleagues (183), that durations 
of B ≥ 1 ms were needed to reach a plateau response. In all the experiments (except figures 11 
and 24) a current density of A = 200 mA was used, which was the only current that gave a 
reproducible contraction; since 200 mA is the maximum current output of the HSE-stimulator II, 
higher currents could not be studied. Another important factor influencing ASM contraction 
is train width: in the present study maximal contraction was achieved at TW ≥ 10 s (figure 11), 
similar to Bosse and colleagues (25; 26), who used a maximum airway contraction at TW = 9 s 
when examining the influence of increased tone (by acetylcholine) on the mechanical properties 
of ASM. However, at TW = 10 s airway contractions took longer to reverse and, more importantly, 
could not be blocked completely by magnesium, indicating that the electrical stimulation was 
more unspecific at this train width and activated both nerve endings and ASM. In order to avoid 
direct activation of ASM TW = 2.5 s was used, but a TW = 5 s would also seem appropriate. 
Since a frequency of F = 50 Hz was used, a train width of TW = 2.5 s implies a series of 125 single 
pulses that were separated by a recovery phase of about one minute (exactly 57.5 s). The duration 
of this phase allowed recovery under normal conditions (figure 10 and figure 12 upper panel), 
but was too short when neostigmine was present. However, as the maximum contraction was 
always reproducible, it is concluded that the lack of complete recovery in figures 12, 15 and 17 is 
not a major limitation. It is important though to note that the different stimulation trains were 
separated by at least 15 min to assure full recovery of the ASM to its physiological ground state 
before the next experimental setting was examined. In addition this period was used to equilibrate 
the slices with the pharmacological agents to be studied next.
5.1.3 Cholinergic neuronal response in PCLS
Acetylcholine release from parasympathetic nerve terminals regulates the airway tone in 
various species including human (14; 32; 61). The enhanced airway contraction after addition 
of neostigmine, an acetylcholine esterase inhibitor (figure 12), indicates locally increased 
concentrations of acetylcholine at the neuroeffector junction (104; 114). Atropine, an unspecific 
inhibitor of muscarinic receptors, almost completely inhibited the neuronal cholinergic contraction 
in PCLS, even in the presence of neostigmine (figure 12). Atropine most probably prevents ASM 
contraction by blockade of the M3 (and M2) receptors on the postsynaptic membrane, such that the 
M3 receptors cannot initiate the contraction via the IP3 pathway (14; 21; 115; 141). The small residual 
bronchoconstriction in the presence of 10 µM atropine may be explained by the blockade of 
presynaptic muscarinic receptors by atropine, preventing the autoinhibitory effect of acetylcholine 
release (14; 21). Furthermore, the release of SP might potentiate the release of acetylcholine from 
cholinergic nerves (14) and trigger the release of bronchoconstrictive tachykinins from excitatory 
NANC (49).
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Having proven the cholinergic mechanism in EFS of PCLS from rat, the method was tested 
against distinct M receptor antagonists at different concentrations to evaluate its potential 
for pharmacological discrimination of drugs. Atropine, ipratropium and 4-DAMP were used 
as representative substances - the first two being unspecific M receptor antagonists and the 
latter a selective M3 receptor antagonist (168). Since repeated stimulations were reproducible 
(figure 13 A) an increase of the inhibitor concentration in consecutive EFS trains is feasible and 
a diminished response can be attributed to the effect of the antagonist and not to fatigue of 
the ASM. Consistently, increasing concentrations of atropine, ipratropium or 4-DAMP inhibited 
EFS-induced airway contractions. Calculated log IC50 values (figure 14), revealed ipratropium 
(-10.0 ± 0.4) being more potent to inhibit EFS evoked airway responses than atropine (-8.8 ± 0.4) 
or 4-DAMP (-8.4 ± 0.3). So far only one other study compared the effect of atropine, ipratropium 
and 4-DAMP in parallel in the same EFS setup, but on twitch responses of guinea pig tracheal 
ring preparations (168). However, equal log IC50 of -8.63 ± 0.04, -8.64 ± 0.04 and -8.61 ± 0.05 were 
found for atropine, ipratropium and 4-DAMP, respectively, which except for ipratropium were 
similar to those determined for rats in this study. Species differences and differences in setup may 
account for the discrepancy. Therefore, the obtained log IC50 values herein seem reasonable and 
the EFS of PCLS is a valuable tool to characterize and discriminate potential anticholinergic drugs.
5.1.4 Reactivity of different airway generations
PCLS have previously been used to study airway responses along the bronchial tree. Smaller airways 
are more responsive to methacholine, serotonin, the TP receptor agonist U46619 and allergens in 
lungs of different species (112; 188; 189). Endothelin-1 contracted airways independent of their 
size (112), indicating that smaller airways are not more sensitive in principle. In the present work 
it was shown that smaller airways are less sensitive to EFS (figure 16). This observation can be 
explained most likely by the decreasing innervation of the bronchial tree towards the peripheral 
regions (14). Thus, parasympathetic bronchoconstriction in the airways appears to be balanced 
by inversely arranged innervation and acetylcholine-responsiveness: rich innervations with low 
acetylcholine-responsiveness in large airways opposed to more sparse innervations with high 
sensitivity in smaller airways.
5.1.5 Role of the TP receptor in neuronal activation
Subthreshold doses of TP receptor agonists (e.g. U46619), i.e. doses which do not evoke airway 
contraction via the TP receptor themselves, have been shown to increase parasympathetic 
cholinergic bronchoconstriction in mice (as measured by lung resistance) (7), guinea pig (lung 
resistance) (176) and dogs (isometric tension) (4; 167). Interestingly, in the study of Takata and 
colleagues (167) the effect was only found for bronchial smooth muscle, whereas tracheal smooth 
muscle was unaffected. This suggests regional differences in airway responsiveness, with smaller 
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airways being more susceptible to TXA. Additionally, Saroea and colleagues (150) suggested 
U46619-induced bronchoconstriction via acetylcholine release in asthmatic subjects. Moreover, 
rat tracheal prostanoid synthesis can be stimulated by activation of M receptor-linked calcium 
mobilization (78). These observations suggested a possible influence of endogenously released 
TXA on EFS in the present model. However, the TP receptor antagonist SQ29548 had no effect 
(figure 17), indicating that EFS-induced airway contractions in the rat are not influenced by TXA. 
This is confirmed by the observation that even a pre-contracting concentration of U46619 did not 
alter the response to EFS (figure 18). These observations are in line with other in vitro studies. For 
instance, Aizawa and Hirose (3) measured airway contraction of canine tracheal strips in response to 
acetylcholine or EFS either in presence or absence of PGF2α or stable TXA2 and found no difference. 
They therefore suggested that the interaction of TXA and cholinergic pathways depends on 
stimulation of vagal sensory endings and activation of the reflex pathway in vivo. This conclusion is 
supported by studies from Underwood and colleagues (176), who discriminated strictly between 
in vitro and in vivo responses to PGD2 and 9α,11β PGF2. In vivo, atropine antagonized PG increased 
airway resistance similar to the TP receptor antagonist SK&F 88046, whereas in vitro (tracheal 
strip) only TP receptor antagonists were effective. Thus, our findings suggest that the reflex arc is 
not complete in PCLS.
An interaction of TP and M receptor pathways may not be limited to prejunctional nerves, 
but may also occur at the ASM itself. Therefore, cumulative concentration-response curves 
were conducted with U46619 in presence or absence of atropine and no difference was found 
(figure 19). This finding is in accordance with in vitro contraction of tracheal strips from guinea 
pigs, where comparable concentration-response curves for TP receptor agonists (U44069, PGD2, 
and 9α,11β PGF2) in the presence or absence of atropine were obtained (176). In contrast, Allen and 
colleagues (7) observed a notable reduction in U46619- (50 - 500 nM) evoked murine tracheal ring 
constriction at 1 µM atropine. They explain their findings by an increased sensitivity of the ASM M3 
receptor to its cognate physiological ligand acetylcholine after stimulation of the ASM TP receptor 
by TXA. However, their model presupposes the existence of an ASM basal tone and constitutive 
release of acetylcholine in the unprovoked airways. Therefore, their data are not conflicting to the 
results herein, as it is assumed that there is no or negligible basal release of acetylcholine in the 
present system, since neostigmine had no effect in un-stimulated PCLS (figure 12). Nonetheless, 
possible species differences can easily be studied with the help of PCLS (34; 111; 145; 188; 189).
5.1.6 Comparison to other in vitro models
Previously, EFS has been almost exclusively studied in the organ bath using trachea, bronchi and 
parenchymal strips. In comparison, PCLS have both advantages and disadvantages. First, organ 
bath studies are limited to the trachea or upper bronchi or to the very distal part of the lungs as in 
parenchymal strips. PCLS from rat lungs allow to study nearly all generations along the bronchial 
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tree. On the other side PCLS are very thin and therefore the percentage of neurons and especially 
ganglia will be lower than in tracheal and bronchial preparations. Second, airway contractions 
in the organ bath are either isotonic or isometric, whereas they are more auxotonic (like in vivo) 
in PCLS. The airways remain embedded in the parenchyma that exhibits tethering forces on the 
airways increasing with contraction. These tethering forces became visible when using a Teflon 
ring that weighs on the outer parts of the slice, so that the tethering forces increase during airway 
contractions. In the absence of the Teflon ring the whole slice contracted and no relaxation 
occurred, implying the lack of sufficient tethering forces (figure 10). So presumably, the Teflon 
ring acts like the attachment of the lung tissue to larger vessels and airways. Third, the PCLS setup 
requires only small buffer volumes of 1 mL and volume could be further decreased to 0.4 mL, 
which is advantageous when expensive substances will be tested. Fourth, PCLS allow to analyze 
airway responses throughout the bronchial tree, allowing to analyze airways down to a diameter 
of 50 µm (111; 188; 189). Thus, the present method will help to further elucidate the role and the 
mechanisms of small airway innervation. In contrast to classic parenchymal preparations for the 
study of peripheral lungs, in which force generation from different sources (ASM, vasculature) 
cannot be distinguished, the present model can specifically attribute contractions to airways or 
vessels along the entire tracheobronchial tree. And finally, the technique of PCLS can be easily 
transferred to other species, including human.
5.2 Active sensitization of rats
In the present study, only healthy animals were examined in EFS of PCLS and their peripheral 
airway innervation could be characterized. In the following section rats were sensitized with OVA 
as a representative experimental animal model of asthma and alterations in nerval responses were 
studied. Haemorrhages in the lung and airway contractions in response to allergen pointed to 
an ongoing inflammatory process and an acute allergic response, but responses to methacholine 
and EFS were the same in control and OVA treated animals excluding a hyperresponsive state. 
IgE levels were determined to prove the immune status of the animals. While OVA alone did not 
raise IgE levels, inactivated Bordetella pertussis organisms, given as adjuvants, were effective in 
increasing the IgE levels more than threefold.
5.2.1 Sensitization scheme
The Brown Norway rat strain was chosen for sensitization, because it presents a more pronounced 
IgE and inflammatory response to allergen challenges than other rat strains (87). The common 
features of Brown Norway rats and human asthma include high IgE levels, EAR, LAR, eosinophilia 
and TH2 cytokine production (87). The sensitization scheme of Brown Norway rats was based on 
the protocol from Glaab and colleagues (60). This group could prove an EAR and LAR in response 
to OVA in vivo after sensitization by two modes of measurement: noninvasive head-out body 
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plethysmography and invasive determination of pulmonary conductance. Moreover, enhanced 
IgE levels and pronounced inflammation were detected by Glaab and colleagues (60). Therefore, 
the sensitization scheme promised to obtain a suitable rat model imitating acute allergic asthma.
The macroscopic observation of increased haemorrhage in sensitized animals versus the control 
animals (figure 20) points to an acute inflammatory process - in which vascular leakage appeared - 
and gives evidence for an immunogenic response to OVA. Confirming this and according to Glaab’s 
and colleagues’ (60) findings, airways contracted in response to OVA in PCLS from sensitized rats, 
whereas no contraction was found in control animals. However, the observed contractions of 
(12 ± 11)% were weak. In contrast, Glaab and colleagues (60) found a pronounced EAR to OVA 
in sensitized animals as both the midexpiratory flow and the pulmonary conductance dropped 
about more than 70% from baseline values. However, those physiological parameters may not 
directly correlate with the decrease in airway caliber in PCLS. Hence, a comparison with an 
allergic response in PCLS itself maybe more appropriate. So far, there is no data published on OVA 
provocation of PCLS from actively sensitized rat, which describe the extent of airway contraction 
exactly. However, in an abstract, Martin and colleagues (109) report of strong and sustained airway 
contractions to allergen in vivo and in PCLS. Surrogate quantitative data may be considered from 
passively sensitized PCLS, i.e. PCLS that were incubated overnight with sera from actively sensitized 
animals. Two studies describe the response of passively sensitized PCLS from rat to OVA (107; 189). 
Wohlsen and colleagues (189), for instance, found an airway contraction of approximately 90% 
after allergen provocation suggesting that a nearly complete airway closure should also be possible 
in PCLS from actively sensitized animals. In principal, the rat is a weak allergic bronchoconstrictor 
and more agonist is necessary to produce airway contractions compared to doses used in guinea 
pigs (87).
Furthermore, the weak contraction found in the present study suggests only a low number of mast 
cells bearing OVA specific IgE and therefore only low mast cell degranulation. This correlates well 
with the unaffected IgE titers during sensitization to OVA (figure 23). IgE titers were only affected 
if in addition heat inactivated Bordetella pertussis organisms were used as adjuvants to induce 
TH2-lymphocyte immune reaction, i.e. TH2-lymphocytes release IL-4, which stimulates 
B-lymphocytes to produce IgE (30). Although IgE titers were elevated by the Bordetella pertussis 
adjuvants, doses of the adjuvants may be critical for a successful allergen sensitization, since the 
activity of the Bordetella pertussis preparation may vary and since other protocols use higher doses 
per animal (e.g. Kucharewicz et al. (88) 1010 organisms, Misawa et Chiba (118) 2 x 1010 organsims) 
than in the present protocol (6 x 109 organisms), which was in accordance to Glaab and colleagues 
(60). A more sophisticated approach could therefore comprise a titration of the adjuvants to 
achieve IgE increases depending on the sensitization with allergen. Since the IgE ELISA determined 
total IgE and not OVA specific IgE and as both sensitized animals and control animals showed 
equal levels of IgE, a quantitative statement on OVA directed immune response cannot be 
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made. However, total IgE levels were quite high even in non-sensitized animals, since they 
exceeded the levels found by Palmans’ group (136) ((1.66 ± 0.80) µg/mL in saline treated rats vs. 
(15.87 ± 1.4) µg/mL in OVA sensitized rats) and Glaab’s group (60) (0.49 ± 0.06 µg/mL in saline 
treated rats vs. (1.61 ± 0.59) µg/mL in OVA sensitized rats) by one and two orders in magnitude, 
respectively.
Since basic IgE levels were still high one may speculate that pre-sensitization of the animals could 
have occurred, in which case an increase due to OVA sensitization would hardly be visible. Pre-
sensitization is conceivable, since in Brown-Norway rats pulmonary inflammation has been 
observed under normal animal room environment due to ambient particles (0.3 - 1 µm in 
diameter) and the number of those particles correlated strongly with the number of eosinophils 
in the bronchoalveolar lavage fluid (133). However, in the present study lung tissue was reserved 
for PCLS preparation, which excluded the determination of eosinophils.
5.2.2 Airway hyperresponsiveness
AHR - an exaggerated airway response to an unspecific stimulus - is a common feature of human 
bronchial asthma. To test whether sensitized rats exhibit an AHR, concentration-response curves 
were performed for methacholine on PCLS from OVA or saline challenged rats (figure 22). However, 
the concentration-response curves were the same in both groups indicating that there was no 
hyperresponsiveness to methacholine after three weeks of sensitization. This was unexpected as 
AHR was reported to occur in rats (89; 136), but in these studies AHR was measured in vivo, whereas 
PCLS are an in vitro method. The lack of an AHR to methacholine might be explained by that 
fact. However, this is questionable because Martin and colleagues (109) performed a comparative 
study on asthmatic airway responses in rats in vivo and in vitro and found AHR to acetylcholine 
and adenosine. The AHR to acetylcholine in vitro only occurred if an EAR was experienced one 
day before in vivo. Although the rats were challenged by OVA one day before PCLS preparation, 
it cannot be guaranteed that an EAR took place and may therefore explain the lack of AHR in the 
present study. Moreover, the time schedule of sensitization could have an important impact on 
the occurrence of an AHR. For instance, Palmans and colleagues (136) found an increase in airway 
responsiveness to carbachol as measured by airway resistance if rats were challenged for two 
weeks by OVA in comparison to PBS-exposed animals, but not if challenge lasted 4 or 12 weeks. 
This concerned the concentration to produce 50% increase in baseline lung resistance. In addition 
to this, a left ward shift in dose response curves of carbachol was observed for animals treated two 
weeks with OVA compared to animals treated for 4 or rather 12 weeks with OVA (136). Since in 
the present study animals were exposed to OVA for three weeks, this may be a critical timeframe 
for whether an AHR is observable or not. The time is especially crucial with respect to airway 
remodelling, i.e. structural changes observed in asthmatics, and Palmans and colleagues (136) 
ascribe their observed difference to different states in airway remodelling. Firstly, the inner airway 
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wall became thicker with two weeks of OVA challenge, which then gradually declined until the 
12th week and secondly, collagen deposition increased with prolonged OVA exposure (136). The 
increased thickness of the inner airway wall enhances the effect of a given ASM contraction (as 
elicited by a bronchcoconstrictor, e.g. carbachol and methacholine) following Poiseuille’s law for 
laminar flow (in other words: with thicker airway wall the inner airway diameter is more reduced 
by the same extent of ASM contraction) and thus contributes to increased airway sensitivity, i.e. 
AHR (120; 136). In contrast, increased collagen deposition increases airway wall stiffness opposing 
airway contraction (90; 136) and increased collagen associated with the ASM layer itself also limits 
airway narrowing (29; 136).
5.2.3 EFS of PCLS from actively sensitized animals
During asthma AHR attributed to nerves can be due to enhanced reflex activity, increased mediator 
release, altered signal transmission, increased receptor-density on neurons and quantitative 
changes in sensory and/or motor neurons (65; 143). Moreover, the ASM may exhibit an enhanced 
sensitivity to neuropeptides and tachykinins or also display an increased receptor expression 
(143) (chapter 1.9). To test whether nerve function is altered after three weeks of sensitization 
and if this is measurable in vitro, PCLS from OVA-sensitized rats were subjected to EFS and the 
airway response was compared to saline treated animals. However, there was no difference in the 
sensitivity to the four basic EFS parameters except for the current (figure 24). A shared frequency-
response curve was found for sensitized and control animals. For the other parameters the curves 
of OVA exposed rats run above the curves of the saline group indicating weaker airway contraction. 
Hence, there is no AHR to EFS found in PCLS, but rather hyporesponsiveness, which is further 
confirmed by a significant reduction in bronchoconstriction to standard EFS (F = 50 Hz, B = 1ms, 
A = 200 mA, TW = 2.5 s) of sensitized rats compared to control rats (figure 25). In consequence of 
the uncertain susceptibility of rat to sensitization and therefore heterogeneous immune state, the 
airway responses of all PCLS - both of sensitized and control rats - were correlated to IgE levels and 
confirmed lesser reactivity with higher IgE (figure 27), i.e. higher immunogenicity. In contrast, the 
airway response to EFS was uncorrelated to the response to allergen suggesting that sensitization 
of rat has no effect on neurally evoked bronchoconstriction (figure 26).
Overall, the findings contradict the expectation of an AHR, which is in contrast to literature. For 
instance, Braun and colleagues (30; 31) found in two EFS studies on mouse trachea a drop in the 
EF50 from 4 Hz in PBS challenged mice to 2 Hz in OVA challenged mice. However, those studies 
were performed in another species and species differences may account for the discrepancy. 
Notably, a Pubmed search on the keywords: rat, airway hyperresponsiveness and electric field 
stimulation was performed and revealed only three results of which one deals with AHR to OVA 
sensitization (50). In that study, confirming the findings herein, there was no AHR to EFS developed 
after both acute and chronic sensitization to OVA and AHR was also not found for acetylcholine. 
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It was concluded, which may also be the case here, that increased release of acetylcholine from 
postganglionic parasympathetic nerves does not occur and that acetylcholine receptor and the 
postreceptor transduction mechanisms are not affected by allergen exposure.
The observed hyporesponsiveness within the present model may result from a fibrotic remodelling 
of the airways resulting in an increased airway wall stiffness or affecting the ASM itself as 
discussed above (chapter 5.2.2) (29; 90; 136). The airways of sensitized animals have possibly been 
precontracted due to inflammatory mediators – thus limiting the extent of EFS-inducible airway 
contraction, but this issue has to be elucidated by the application of ASM relaxant agonists.
5.3 Comparison of different species in EFS of PCLS
In the present the study an electric field was applied to PCLS from different mammals allowing 
the species comparison of neuronally triggered airway responses under identical conditions. 
Species were heterogeneous in their response (table 6): In rats, sheep, guinea pigs, marmosets 
and humans, bronchoconstriction was caused by cholinergic innervation. Moreover, in guinea pig 
and human PCLS also activation of eNANC nerves led to airway contractions. The blockade of 
airway relaxation in marmosets by the inhibition of β-receptors and NO synthase points towards 
adrenergic and iNANC innervation in this species.
5.3.1 General considerations on EFS of PCLS
In the preceding part rat EFS was introduced as a means to study neural responses in PCLS and 
the following EFS settings were found to be effective (152): F = 50 Hz, B = 1 ms, A = 200 mA and 
TW = 2.5 s. The same parameters were also used to stimulate PCLS from mice, guinea pigs, sheep, 
marmosets and humans and evoked characteristic airway contractions in each species (figure 28), 
except for the mouse. The neural mediation of these responses was proven by the inhibitory effect 
of magnesium concentrations (10 mM) high enough to prevent voltage-induced calcium entry 
and the release of neurotransmitters at the nerve terminals (40; 53) (table 5). The contractions to 
exogenous methacholine were not affected by magnesium, excluding the possibility that the high 
magnesium concentrations altered ASM physiology itself. These findings show that the EFS, like in 
rats, acts also in the other species on neurons and not directly on ASM.
Differences in stimulation conditions compared to other ex vivo EFS studies on lung tissue (183) 
can be due to species or tissue variability, different electrode geometry, and different ionic strength 
of the cell culture medium, which all influence the electric field. In the present study, different 
species were compared in an identical setup, including nearly identical tissue preparation. These 
identical conditions are the basis for the conclusion about the differences between species with 
respect to neurally mediated bronchoconstriction.
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Under the standard conditions (F = 50Hz, B = 1 ms, A = 200 mA, TW = 2.5s) mice showed 
no significant response. However, EFS elicited contractions in murine tracheal preparations 
in previous studies (11; 12; 93) and in line with that neurally-evoked bronchoconstriction was 
observed in murine PCLS at higher electric fields (figure 29). Higher electric fields were also 
required in studies by Braun and colleagues (31) as well as Larsen and colleagues (93), who used 
pulse durations of 2 ms when stimulating murine tracheal smooth muscle segments. In contrast, 
Bachar and colleagues (11; 12) only used pulse durations of 0.8 ms, but train widths lasted 60 s 
and were therefore much longer than the 2.5 s within this study. Hence, the observations made 
here are reasonable concluding that murine preparations are less susceptible to EFS and require 
harsher EFS conditions. Nonetheless, those harsher conditions seem still to neurons specifically, 
since magnesium blocked the EFS-induced airway response (figure 29 C). In ovine PCLS, on the 
other hand, airways were highly excitable (figures 28 and 30) and nerve activation was observed 
already at low frequencies or even after one single electrical stimulus (0.4 Hz at train width 2.5 s). 
Overall, the EF50 values observed in the present study are in line with the literature. The EF50 of 
(0.5 ± 0.2) Hz is in the range of that for ovine bronchial rings and tracheal segments of about 
0.2 Hz (156). The rat EF50 of (16.5 ± 0.8) Hz was equal to that of (16.7 ± 4.9) Hz in the previous 
part of the study and comparable to (19.3 ± 4.3) Hz from isometric tension studies of rat tracheal 
smooth muscle (61). The guinea pig EF50 of (7.0 ± 1.2) Hz is close to the 5.3 Hz and 3.7 Hz observed 
by Altiere and colleagues (8) when studying cholinergic responses in the trachea and tachykinergic 
responses in the bronchus, respectively. For human airways, the EF50 of (8.1 ± 0.8) Hz herein is 
close to (8.9 ± 0.4) Hz that was obtained in human bronchi before (47). Among all species studied 
here, the EF50 values of guinea pigs ((7.0 ± 1.2) Hz) are closest to that of humans ((8.1 ± 0.8) Hz), 
providing another argument for the conclusion that guinea pig airways are a reasonable proxy for 
human airways.
The differences between the species within this study are not explained by differences in ASM 
cells, because the responses to methacholine are very similar in all species (68; 111; 145; 151; 155; 
188) and the experiments with magnesium als exclude direct electric activation of ASM. Possible 
explanations are differences in neurotransmitter release or neurotransmitter degrading enzymes 
such as the acetylcholine esterase that may vary in amount or activity (86; 113; 148). However, one 
may speculate that the type of innervation, i.e., cholinergic, adrenergic, eNANC or iNANC, is the 
most relevant reason for the differences between species. For instance the repetitive reversible 
contraction in rat is cholinergic (152), whereas the steady contraction without relaxation in guinea 
pigs (figure 28) suggests a mechanism other than a cholinergic one, in which the neurotransmitter 
is not metabolized.
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5.3.2 Pharmacological characterization of distal airway innervation
The type of innervation was addressed by pharmacological agents: the muscarinic antagonist 
atropine (141) was used to show involvement of parasympathetic cholinergic nerves, whereas 
the TRPV1 channel activator capsaicin (126) or the unspecific TRP channel blockers SKF96365 
and Ruthenium red (140) were used to demonstrate eNANC nerves. Relaxant nerve responses 
were addressed by the sympathetic adrenergic antagonist propranolol (82) or by the NO synthase 
inhibitor L-NAME to prevent NO release from iNANC nerves (95).
Atropine blocked the EFS-induced bronchoconstriction in PCLS from rats, guinea pigs, sheep, 
marmosets and humans (figures 31 and 33), indicating that these species receive cholinergic 
innervation in the distal part of their lungs. These findings extend former studies on larger airways 
(8; 14; 54; 61; 70; 158) and they are important, because innervation is unevenly distributed along 
the tracheobronchial tree (8). This is also true for tachykinergic innervation in guinea pigs that so 
far was thought to supply predominantly the large airways (8). In this species distal airways seem 
to be supplied by both cholinergic and tachykinergic nerves, as shown by the effects of atropine 
and the TRP channel antagonists (figure 33). In contrast to the rats, in which cholinergic responses 
are weaker in smaller airways (152), distal airways from sheep or human were quite susceptible to 
EFS-induced cholinergic bronchoconstriction (figure 31), indicating relatively strong innervation of 
peripheral airways in these species. The residual airway contractions in the presence of atropine 
may be due to eNANC activation, or blockade of presynaptic muscarinic receptors by atropine, 
preventing the autoinhibitory effect of acetylcholine release (14; 21) or due to release of SP that 
might potentiate the release of acetylcholine from cholinergic nerves (14).
Various types of TRP channels are expressed in the mammalian lung and are involved in the 
regulation of airway functions, in which particularly TRPV1 and TRPV4 play an important role. 
TRPV1 channels are generally expressed in non-myelinated C-fiber afferents, which innervate the 
airways and contain sensory neuropetides (79). Activation of TRPV1 cannels on nerves induces 
calcium influx into neurons, membrane depolarization and action potentials. Such excited 
chemosensitive nerves correspond to eNANC nerves, which induce bronchonconstriction by the 
release of SP or a related tachykinin (9). Therefore, the effects of capsaicin, a potent TRPV1 agonist 
(79; 126), were studied to estimate the role of eNANC innervation in the various species. Notably, 
only airways of guinea pigs and humans responded to capsaicin providing further evidence for 
the presence of tachykinergic nerves in the distal lung of these species (figure 32). Undem and 
coworkers (175) reported contractions of (66 ± 10)% in guinea pig bronchi towards capsaicin 
and Spina with colleagues (158) made similar observations in human airways, albeit the effects 
were smaller here (1µM: (2 ± 3)%, 10µM: (14 ± 13)% and with 100µM capsaicin (44 ± 40)% of the 
maximal contraction by 10-4 M methacholine). Also, findings by Lundberg and colleagues (100) 
support the notion that human airways are less responsive to capsaicin than those from guinea 
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pigs, by showing that guinea pig tracheas are 1000-fold more sensitive to SP and 100-fold more 
sensitive to capsaicin than human bronchi. Further on, Lundberg’s and colleagues’ (100) study 
also supports the observation made in the present work that not all human airways are capsaicin 
sensitive. From studies with transmural EFS of human segmental bronchi, they report two 
different scenarios: one where contractions were abolished by atropine and another one where 
only tetrodotoxin (specific antagonist of voltage-gated sodium channels on nerve cells), but not 
atropine was effective. These findings suggest the existence of two types of human airways: either 
solely innervated by cholinergic nerves or innervated by both cholinergic and eNANC nerves. 
That capsaicin failed to evoke clear bronchoconstriction in PCLS from marmosets is in line with 
data presented for marmoset trachea and bronchus, which weakly contracted by (2.3 ± 2.8)% 
and (8.0 ± 6.6)% of maximal contraction by 10-4 M methacholine, respectively, after application 
of 100 µM capsaicin (158). In conflict to capsaicin responses in ovine PCLS, sheep lambs exerted 
a reduction in tidal volume from 91 mL to 36 mL when capsaicin (5 µg/kg) was injected 
intravenously (10). This opposing finding may be explained either by regional differences along 
the tracheobronchial tree (trachea/bronchus vs. peripheral airways in PCLS) (8) or by reflex arcs 
in vivo (79), which are destroyed in the PCLS preparation. In rat and mouse bronchi, but probably 
also in marmoset and sheep airways, capsaicin may play a more prominent role in the activation 
of sensory nerves of the inhibitory system than in the excitatory system (105; 164).
Nervous stimulation can also cause bronchorelaxation via either sympathetic or iNANC nerves (32; 
143). In the present study, dilation of airways appeared only in PCLS from marmoset after multiple 
EFS (figures 28 and 34). The effects of propranolol and L-NAME demonstrate that this relaxant 
response was due to both sympathetic and iNANC innervation, because only the combination 
of the two inhibitors was effective in blocking the relaxant response. Although power analysis 
revealed the possibility of sympathetic contribution, iNANC contributions seem also to be involved 
for two reasons: Firstly, L-NAME prevented the return to baseline levels during EFS (figure 34 C, 
2nd train) and secondly Spina and colleagues (158) reported relaxations in marmoset tracheae and 
bronchi at capsaicin concentrations as high as 100 µM after the tissue was precontracted with 
methacholine. The marmoset maybe a useful model to study relaxant innervation of the lung, 
as interferencies with precontracting agents can be excluded. Whether the peripherial airways 
of the other species are innervated by relaxant nerves still has to be elucidated, because usually 
relaxation becomes apparent only in precontracted airways (43; 146).
In summary cholinergic innervations were found to contract airways of rats, guinea pigs, sheep, 
marmosets and humans. In addition eNANC nerves contracted guinea pig and human airways. 
Furthermore, the dilation of airways in marmoset PCLS was attributed to sympathetic and iNANC 
responses (table 6).
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5.3.3 Phylogenetic considerations
Airway pharmacology varies strikingly between species, not only with respect to neural 
transmission, but also with respect to various mediators and transmitters. For instance, airways 
from rodents, marmosets or rhesus monkeys do respond weakly or not at all to LTs (67; 155), that 
readily contract airways in humans (37), cynomolgus, baboons (155) and guinea pigs (46; 66). All 
these studies suggest that, regarding airway pharmacology, guinea pigs resemble humans more 
closely than mice or rats do (121; 161). 
Species Cholinergic Adrenergic eNANC iNANC
Mouse -
Rat + -
Guinea Pig + +
Sheep + -
Marmoset + + - +
Human + +
eNANC, excitatory nonadrenergic noncholinergic; iNANC, inhibitory nonadrenergic noncholinergic; +, proven; 
-, insignificant.
Table 6: Peripheral airway innervation of distinct mammals as verified in the current examination
Homo (human)
Callitrichidae (→ marmoset)
Cavia (guinea pig)
Artiodactyla (→ sheep)
Primates
Rodentia
Cetartiodactyla
Rattus (rat)
Mus (mouse)
≥4
15
14
14
≥13
0
Myomorpha
Hystricomorpha
Figure 35:  Phylogenetic  relationships  among  the  examined  species. Relationships are deduced from 
Murphy and colleagues (122), who analysed 9779 base pairs from 15 nuclear and three mitochondrial DNA 
genes among 64 placental mammals and two marsupials. Except for the sheep all animal belong to one clade, 
the Neotropical order of Xenarthra. There is current debate on rodent monophyly or polyphyly and wether 
the guinea pig is a rodent or not (36). However, in line with D’Erchia’s and colleagues’ (36) phylogentic study 
on the whole mitchondrial genome, the Cavia separates earlier than Myomorpha and is traditionally classified 
as Hystricomorpha. The marmoset is considered as a non-human primate and belongs to the family of 
Callitrichidae, for which Murphy and colleagues (122) refer to the Callimico. Direct data for sheep also lacked 
and therefore the sheep was categorized to Artiodactyla. Numbers indicate the total count of branches 
beginning from human up to the examined species as suggested by Murphy and colleagues (122) for the 
interrelationship of their 66 studied Amniota, in which the minimum evolution topology was estimated by 
neighbour joining using maximum likelihood distances.
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The physiological observations might suggest a close phylogenetic relationship between guinea 
pigs and humans. Therefore, a phylogenetic tree based on Murphy’s and colleagues’ examinations 
(122) was drawn for all species within in this study (figure 35). Interestingly, however, this mapping 
does not indicate an exceptional close relationship between guinea pigs and humans, although 
this may be due to the selection of genes that were not specific for the lungs.
5.4 Conclusion
PCLS are widely used in airway pharmacology. In the present study EFS of PCLS was introduced as a 
novel way to study neural airway responses. The finding that in PCLS airways contract in response 
to electrical fields and that this response is sensitive to magnesium indicates that terminal nerves 
remain intact in this preparation and can be activated specifically. PCLS were prepared from 
different species including humans and peripheral neural airway responses were characterized. 
The present findings suggest that airways of rats, guinea pigs, sheep, marmosets and human do 
all receive cholinergic innervations. Moreover, distal airways from guinea pigs and humans also 
receive eNANC innervations, whereas marmoset airways display relaxations by sympathetic and 
iNANC nerves.
In the allergic rat model no AHR was observed, indicating that increased release of acetylcholine 
from postganglionic parasympathetic nerves does not occur and that acetylcholine receptors and 
the postreceptor transduction mechanisms are not affected by allergen exposure in rat.
Since the cholinergic response can be influenced pharmacologically in EFS of PCLS and log IC50 for 
antagonists can be detrmined, this new method allows the screening of drugs affecting neurally 
evoked bronchoconstriction. As the guinea pig resembled the human response profile best, this 
species is particularly suitable for studies on the role of peripheral airway innervations and their 
involvement in human lung diseases.
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Chronic airway diseases, such as bronchial asthma and chronic obstructive pulmonary disease 
(COPD), are the fourth-leading cause of death in developed countries and have a high personal, 
societal, and economical impact. Recurring inflammation is one characteristic of those diseases 
leading to airway remodelling and modulating the function of nerves resulting in excessive 
bronchoconstriction. The precision-cut lung slice (PCLS) technique is widely used in pulmonary 
pharmacology, but neurally-induced bronchoconstriction has not been studied yet. Hence, the 
aim of this study was to develop a system, which specifically activates nerves within PCLS of 
different species, allowing the investigation of neural function and its pharmacological interference 
throughout the whole lung - also in an allergic animal model.
Electric field stimulation (EFS) is considered to activate nerve endings in tissue preparations. 
Therefore, a device was constructed in which the PCLS were faced by two platinum electrodes 
and which delivered serial rectangular electric stimuli. EFS-induced bronchoconstriction in PCLS 
was monitored by videomicroscopy.
EFS of PCLS was first established for the rat. EFS conditions were systematically studied and stable 
repeated airway contractions were obtained at a frequency of 50 Hz, pulse duration of 1 ms, 
current of 200 mA and train width of 2.5 s. Magnesium antagonized airway contractions induced 
by EFS, but not by methacholine, indicating that they are neurally evoked. The EFS-triggered 
contractions were increased by the acetylcholine esterase inhibitor neostigmine and were highly 
reproducible, which allowed the study of muscarinic antagonists in consecutive EFS-trains. The 
decadic logarithmic inhibitory concentration of half-maximal effect (log IC50 M) of antagonists 
was determined in EFS of PCLS and revealed ipratropium (-10.0 ± 0.4) being more potent than 
atropine (-8.8 ± 0.4) and 4-DAMP (-8.4 ± 0.3). Furthermore, it was tested if thromboxane facilitates 
cholinergic bronchoconstriction by using the thromboxane prostanoid receptor antagonist 
SQ29548, but no effect was observed. In EFS of PCLS on different airway sizes, larger airways 
showed stronger response than smaller ones.
In a model of allergic asthma, Brown-Norway rats were sensitized against ovalbumin (OVA). 
Besides haemorrhages in the lung also airway contractions in PCLS after OVA-provocation were 
found, pointing to a persisting inflammation and an acute allergic response, respectively. However, 
in PCLS from these rats no airway hyperresponsiveness was found in response to methacholine 
or EFS.
Since airway responses are known to exhibit considerable species differences, the neural responses 
of PCLS prepared from mice, guinea pigs, sheep, marmosets and humans were examined. Peripheral 
neurons were activated either by EFS or additionally, in order to probe excitatory nonadrenergic 
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noncholinergic (NANC) nerves, by capsaicin. Bronchoconstriction in response to EFS varied 
between species in magnitude ((2 ± 2)% in mouse to (61 ± 26)% in guinea pig) and sensitivity 
(half-maximal response in frequency-response curves: (0.5 ± 0.2) Hz in sheep to (23 ± 7) Hz in 
marmoset). As in rats, atropine antagonized the EFS-induced bronchoconstriction in PCLS from 
guinea pigs, sheep, marmosets and humans. Capsaicin caused bronchoconstriction only in human 
and guinea pig lungs. Transient receptor potential channel antagonists (SKF96365/Ruthenium red) 
inhibited airway contractions after EFS or capsaicin addition in guinea pigs. Only marmoset airways 
showed airway dilation after multiple EFS and this was blocked by propranolol and L-NAME. 
In conclusion, the findings within this study show that nerve endings remain intact in PCLS. 
The present method is useful to study neurogenic responses in airways of different size and 
pharmacological interventions are possible. In rat PCLS, lesser sensitivity to EFS with smaller 
airways is in contrast to the response of exogenously applied methacholine, which suggests 
that parasympathetic bronchoconstriction in the airways seems to be balanced by inversely 
arranged innervation and acetylcholine-responsiveness: rich innervations with low acetylcholine-
responsiveness in large airways opposed to more sparse innervations with high sensitivity in smaller 
airways. In the rat model of allergic asthma, increased release of acetylcholine from postganglionic 
parasympathetic nerves does not take place and acetylcholine receptors and the postreceptor 
transduction mechanisms are not affected after allergen sensitization. As in rats, airways of guinea 
pigs, sheep, marmosets and humans do all receive cholinergic innervations. Moreover, distal guinea 
pig and human airways also receive excitatory NANC innervations. Marmoset airways even display 
relaxations by sympathetic and inhibitory NANC nerves. As guinea pig resembled the human 
response profile best, this model may be particularly suited for studies on the role of peripheral 
airway innervation and its involvement in human lung diseases.
7 Deutsche Zusammenfassung 69
7 Deutsche Zusammenfassung
Chronische Atemwegserkrankungen, wie Asthma bronchiale und die chronisch obstruktive 
Lungenerkrankung (COPD), sind die vierthäufigste Todesursache in Industrieländern und haben 
einen bedeutenden persönlichen, sozialen und ökonomischen Einfluss. Diesen Erkrankungen 
liegt eine chronische Entzündung zugrunde, die zum Umbau der Atemwege führt und die 
Nervenfunktion moduliert, so dass eine exzessive Bronchokonstriktion auftritt. Lebende 
Lungenschnitte (PCLS) werden in der Lungenpharmakologie zu unterschiedlichen Zwecken 
genutzt, aber neuronale Fragestellungen wurden in PCLS noch nicht untersucht. Das Ziel dieser 
Arbeit war es daher, ein System zu entwickeln, das spezifisch die Nerven in PCLS verschiedener 
Spezies aktiviert, um so die neuronale Funktion und ihre pharmakologische Beeinflussung in 
Atemwegen zu studieren. Ein Tiermodell des allergischen Asthmas sollte Aufschluss über eine 
etwaige Veränderung der Nervenfunktion in der Krankheit geben.
Elektrische Feldstimulation (EFS) wird genutzt, um Nervenendigungen in Gewebepräparationen 
zu aktivieren. In dieser Arbeit wurde die EFS an PCLS bewerkstelligt, indem PCLS zwischen zwei 
Platinelektroden platziert wurden und seriell elektrische Rechteckimpulse angelegt wurden. Die 
Bronchokonstriktion nach EFS wurde mit Hilfe der Videomikroskopie verfolgt.
Das Modell der EFS wurde zuerst an PCLS der Ratte entwickelt. Die das elektrische Feld bestimmenden 
Bedingungen wurden systematisch untersucht und reproduzierbare Atemwegskontraktionen 
wurden bei einer Frequenz von 50 Hz, einer Reizbreite von 1 ms, einem Strom von 200 mA und einer 
Seriendauer von 2,5 s gefunden. Die EFS-induzierte Bronchokonstriktion ist neuronal bedingt, da 
Magnesium die Bronchokonstriktion in der EFS antagonisierte, aber nicht die durch Methacholin 
hervorgerufene Kontraktion der glatten Muskulatur der Atemwege. Die durch EFS ausgelösten 
Kontraktionen wurden durch den Acteylcholinesteraseinhibitor Neostigmin verstärkt und waren 
höchst reproduzierbar, sodass muskarinische Rezeptorantagonisten in aufeinanderfolgenden EFS-
Serien untersucht werden konnten. Darin wurde die logarithmische inhibitorische Konzentration 
des halbmaximalen Effekts (log IC50 M) ermittelt und es zeigte sich, dass Ipratropium (-10.0 ± 0.4) 
potenter als Atropin (-8.8 ± 0.4) und 4-DAMP (-8.4 ± 0.3) wirkte. In einem anderen Ansatz wurde 
geprüft, ob Thromboxan die parasympathisch-cholinerge Bronchokonstriktion begünstigt, indem 
SQ29548 als Thromboxanprostanoid-Rezeptor-Antagonist eingesetzt wurde. Hierbei konnte 
jedoch kein Effekt festgestellt werden. In der EFS an PCLS mit unterschiedlicher Atemwegsgröße 
zeigte sich, dass größere Atemwege reaktiver waren als Kleinere.
Als Tiermodell des allergischen Asthmas dienten gegen Ovalbumin sensibilisierte Brown-Norway 
Ratten. Hämorrhagien in der Lunge und Atemwegskontraktion in PCLS nach Allergenprovokation 
deuteten auf eine bestehende Entzündung und eine akute allergische Reaktion hin. Allerdings trat 
Atemwegshyperreaktion weder nach Methacholinzugabe noch nach EFS auf.
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Neben der Ratte wurde die neuronale Reaktion in PCLS von Maus, Meerschwein, Schaf, Marmoset 
und Mensch untersucht, da die Innervation der Atemwegsmuskulatur in verschiedenen Spezies 
sehr unterschiedlich ausfällt. Periphere Neuronen wurden per EFS oder zusätzlich durch Capsaicin 
als Stimulanz exzitatorischer nicht-adrenerger nicht-cholinerger (NANC) Nerven aktiviert. Die 
durch EFS hervorgerufene Bronchokonstriktion variierte zwischen den Spezies im Ausmaß 
((2 ± 2)% in der Maus bis (61 ± 26)% im Meerschwein) und in der Sensitivität (halbmaximale 
Antwort in der Frequenz-Wirkungskurve: (0,5 ± 0,2) Hz im Schaf bis (23 ± 7) Hz im Marmoset). 
Wie bei der Ratte antagonisierte Atropin die EFS induzierte Bronchokonstriktion in PCLS des 
Meerschweins, Schafs, Marmosets und Menschen. Capsaicin bewirkte eine Bronchokonstriktion 
nur in humanen PCLS sowie in denen des Meerschweins. Ruthenium Red und SKF96365 sind 
Inhibitoren an TRP-Kanälen (engl. transient receptor potential channels) und antagonisierten die 
Atemwegskontraktion im Meerschwein sowohl nach EFS als auch nach Zugabe von Capsaicin. 
Lediglich Marmoset-Atemwege zeigten eine Relaxation in der EFS an PCLS, die sensitiv gegenüber 
Propranolol und L-NAME war.
Zusammenfassend konnte gezeigt werden, dass Nervenendigungen in PCLS intakt bleiben. 
Die entwickelte Methode eignet sich dazu neurogene Mechanismen in Abhängigkeit der 
Atemwegsgröße zu untersuchen und pharmakologische Beeinflussungen der EFS-induzierten 
Antwort sind möglich. Die geringere Antwort mit kleineren Atemwegen in der EFS widerspricht 
der höheren Anfälligkeit kleiner Atemwege nach äußerer Zugabe von Methacholin. Dies deutet 
jedoch auf eine geschickte Regulation der parasympathischen Bronchokonstriktion hin: Größere 
Atemwege scheinen stärker innerviert als Kleine, sind aber dafür weniger anfällig gegenüber 
Acetylcholin als die Kleinen. Im Rattenmodell des allergischen Asthmas konnte gezeigt werden, 
dass die cholinerge Antwort unverändert ist. Entsprechend der Ratte weisen die Spezies 
Meerschwein, Schaf, Marmoset und Mensch alle cholinerge Innervierung auf. Zudem sind distale 
Atemwege des Meerschweins und Menschen noch exzitatorisch NANC innerviert, wohingegen 
die Dilation der Atemwege des Marmosets durch adrenerge und inhibitorsiche NANC Nerven 
bestimmt ist. Meerschwein PCLS wiesen die größten Gemeinsamkeiten mit humanen PCLS auf, 
und dürften sich deshalb in Zukunft besonders für klinisch relevante Untersuchungen neuronaler 
Atemwegsreaktionen eignen.
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